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Abstract
Tumor growth often outpaces its vascularization, leading to development of a hypoxic
tumor microenvironment. In response, an intracellular hypoxia survival pathway is initiated
by heterodimerization of hypoxia-inducible factor (HIF)-1α and HIF-1β, which subsequently
upregulates the expression of several hypoxia-inducible genes, promotes cell survival and
stimulates angiogenesis in the oxygen-deprived environment. Hypoxic tumor regions are
often associated with resistance to various classes of radio- or chemotherapeutic agents.
Therefore, development of HIF-1α/β heterodimerization inhibitors may provide a novel
approach to anti-cancer therapy. To this end, a novel approach for imaging HIF-1α/β
heterodimerization in vitro and in vivo was developed in this study. Using this screening
platform, we identified a promising lead candidate and further chemically derivatized the
lead candidate to assess the structure-activity relationship (SAR). The most effective first
generation drug inhibitors were selected and their pharmacodynamics and anti-tumor
efficacy

in

vivo

were

verified

by

bioluminescence

imaging

(BLI)

of

HIF-1α/β

heterodimerization in the xenograft tumor model. Furthermore, the first generation drug
inhibitors, M-TMCP and D-TMCP, demonstrated efficacy as monotherapies, resulting in
tumor growth inhibition via disruption of HIF-1 signaling-mediated tumor stromal
neoangiogenesis.
v
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Chapter 1: Introduction
1.1 Oxygen and oxygen-dependent metabolism
Oxygen, a gas that plays a vital role in all life on earth, controls respiration and
metabolic processes of aerobic organisms. Under normal physiological condition, a resting
adult consumes approximately 3.5 ml of oxygen per kilogram of body mass every minute. In
the human body, the delivery of oxygen is accomplished by an elaborate arterial and venous
circulatory network, where oxygen diffuses from areas of higher oxygen partial pressure to
areas of lower oxygen partial pressure. De-oxygenated blood is circulated via venous
network to the lungs while it is oxygenated again. Oxygenated blood then distributes to the
body where needed. However, due to the limitations in diffusion, oxygen can only be
transported to cells within 100–200 µm from the capillary (Rouwkema et al., 2008) (Fig.1).
When oxygen supply is ample, living cells preferentially produce energy through
aerobic respiration to convert nutrients, such as glucose, into adenosine triphosphate (ATP)
(Fig.2). Aerobic respiration composed a set of metabolic reactions, including glycolysis,
oxidative decarboxylation of pyruvate, citric acid cycle and oxidative phosphorylation. During
aerobic respiration, exogenous oxygen is used in the final step of oxidative phosphorylation.
In the inner mitochondrial membrane, the high-energy electrons released from coenzyme
NADH produced from the citric acid cycle pass through a set of enzymes called the electron
transport chain (ETC), and release the energy to pump protons across the inner membrane
of mitochondria, which generates a proton gradient (chemiosmosis potential) across the
intermembrane space. This proton gradient drives protons to flow back across the
membrane through the ATP synthase. The flow of proton forces the rotation of a part of the
enzyme, generating ATP by phosphorylation of adenosine diphosphate (ADP). Finally, the
low-energy electrons passing through the electron transport chain are transferred to oxygen,
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a strong oxidizing agent to accept the low-energy electrons. Oxygen then combines with a
pair of electrons and two protons to form water (Lehninger et al., 2013).
In one complete cycle of aerobic respiration, a total of 38 ATP molecules are
generated per each oxidized glucose molecule; whereas in the absence of oxygen, the cells
are forced to switch to anaerobic respiration and use electron acceptors other than oxygen.
Importantly, the anaerobic respiration is much less efficient and yields only 2 ATP molecules
per each glucose molecule. Both aerobic and anaerobic respiration share the initial pathway
of glycolysis to produce pyruvate, but only aerobic metabolism continues with the citric acid
cycle and oxidative phosphorylation. In anaerobic respiration, cells have pyruvate oxidized
with NADH, ending with the final production of ethanol or lactic acid (Fig.2B).
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capillary The
Figure 1. A diagram of human circulatory system and gas exchange in capillary.
human circulatory system consists of two parts: a) Pulmonary loop: the oxygen-depleted
oxygen
blood circulates from the right atrium and ventricle of the heart to the lung via pulmonary
artery. The gas exchange takes place in the lung via single layer capillaries,
capillaries where CO2 is
released from the blood and oxygen is picked up. Then the oxygen
oxygen-rich
rich blood return to the
left atrium via pulmonaryy vein. b) Systemic loop: the blood circulates to all parts of the body
except the lungs. The oxygenated blood pumps from the heart through the left ventricle to all
the rest of the body to supply oxygen and collect CO2 and waste via interweaving network of
capillaries. The oxygen-depleted
depleted blood then returns back to the right atrium and starts a new
pulmonary circulation cycle to be re-oxygenated. The capillary wall is a one-layer
one
endothelium that allows gas and lipophilic molecul
molecules
es to pass through by bidirectional
diffusion depending on osmotic gradients. However, due to the limitations in diffusion,
oxygen can only be transported to cells within 100
100–200 µm
m from the capillary.

3

Figure 2. A diagram of cellular respiration including glycolysis, citric acid cycle, and
oxidative phosphorylation in the electron transport chain. The process of glycolysis
begins with phosphorylation of glucose by hexokinase (I, II, and III) to form glucose 6phosphate. Subsequently, fructose 1,6-disphosphate is formed by 6-phosphofructo 1-kinase
at the cost of two ATP molecules. Next, the cleavage of fructose 1,6-disphosphate into two
pyruvate molecules by the aldolase produces 4 ATP and 2 NADH. As a result, the entire
process of glycolysis generates a net gain of 2 ATP molecules and 2 NADH. Glucose + 2
NAD+ + 2 Pi + 2 ADP → 2 pyruvate + 2 NADH + 2 ATP + 2 H+ + 2 H2O + heat. A) In
anaerobic respiration, to convert NADH back to replenish the limited supply of NAD+, most
cells have pyruvate oxidized with NADH, ending with the final production of ethanol or lactic
acids. B) In aerobic respiration, cells can further utilize pyruvate and NADH + H+ from
glycolysis to produce additional 34 ATP molecules in the citrate acid cycle and oxidative
phosphorylation pathway. First, pyruvate is oxidized to acetyl-CoA and CO2 by pyruvate
dehydrogenase complex before entering to citric acid cycle within the mitochondrial matrix.
Next, acetyl-CoA (2 carbons) continues to oxidize with oxaloacetate (4 carbons) to form
citrate (6 carbons), which later modifies to become α-ketoglutarate (5 carbons) and CO2.
When α-ketoglutarate is oxidized to succinyl-CoA (4 carbons), another CO2 is released.
Following production of succinate, fumarate, malate, and back to oxaloacetate, the net
energy produced by one cycle is 3 NADH, 1 FADH2, and 1 GTP. Since two acetyl-CoA are
generated from each glucose molecule, a total of 6 NADH, 2 FADH2, and 2 GTP are
produced for one fully oxidized glucose during the citric acid cycle. The next oxidative
phosphorylation occurs in the inner mitochondrial membrane, which generates the high
transfer potential electrons. When released from coenzyme NADH, the high transfer
potential electrons pass through a set of enzymes called the electron transport chain and
release the energy to pump protons across the inner membrane of the mitochondria. The
established proton gradient (chemiosmosis potential) across the intermembrane space then
drives protons to flow back across the membrane via a large enzyme called ATP synthase.
The flow of proton forces the rotation of a part of the enzyme, generating ATP from the
phosphorylation of ADP. Finally, the low-energy electrons passing through the electron
transport chain are transferred to oxygen, a strong oxidizing agent to accept the low-energy
electrons. Oxygen then combines with a pair of electrons and two protons to form water.
The figure was adapted from RegisFrey, [CC-BY-SA-3.0 (http:// creativecommons.org
/licenses/by-sa/3.0) (2011).
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1.2 Hypoxia and malignancy
When oxygen consumption in the body is elevated in events such as exercise, the
body can quickly adapt to the need for increased oxygen by accelerating cardiac output and
increasing respiration rate to elevate blood oxygenation. However, if these adjustments are
insufficient to deliver adequate supply of oxygen to the tissues, compensatory changes in
oxygen delivery and utilization are initiated by adjusting arterial compliance to allow more
blood flow to reach vital organs. At some point, this compensation may still fail to supply
adequate oxygen, which will result in a state of reduced oxygen availability, known as
hypoxia. Normally, the partial pressure of oxygen (PO2) in dry air at sea level is 159 mm Hg,
the PO2 in arterial blood is about 100 mm Hg, the PO2 in mean capillary is about 50 mm Hg,
and the PO2 in trans-capillary tissues is between 20 and 40 mm Hg. Hypoxia in tissues is
defined as the PO2 below 10 mm Hg (Nunn, 1993, Loiacono and Shapiro, 2010).
During hypoxia, the activation of the hypoxia-adaptive responses triggers the
production of pro-survival factors and decreases metabolic consumption via posttranslational modification of existing proteins or even changes in gene transcription and
protein synthesis. Nevertheless, most cells fail to survive long under chronic hypoxia,
especially the oxygen-sensitive cells in the brain and heart.
A hypoxia environment has been shown to induce genome instability in cells. When
genetic errors exceed the cells’ capacity to repair, genetic changes and mutations would
follow (Liu et al., 2012, Sung et al., 2011). Some cells may acquire resistance to hypoxia.
These mutated cells with a selective growth advantage often expand much more rapidly in
hypoxic environment. If overcoming restricted growth checkpoints and regulatory pathways,
they may eventually manifest as malignant cells and transform into cancer (Hanahan and
Weinberg, 2000, Vanderkooi et al., 1991).
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1.3 Hypoxia and cancer
The classic hallmarks of cancer proposed by Hanahan and Weinberg listed six
biological characteristics acquired during the multi-step development of human cancer,
which include sustained cell proliferative signaling, evasion of growth suppressors, cell
death resistance, immortal replication, induction of angiogenesis and activation of
metastasis and invasion, with three emerging hallmarks added to this list: reprogramed
energy metabolism, tumor-promoting inflammation and evasion of destructive immunity
(Hanahan and Weinberg, 2011, Hanahan and Weinberg, 2000).
During

tumor

progression,

rapid

cellular

proliferation

and

highly

abnormal

vascularization often induces inadequate oxygen supply within tumor sites. Although some
of the effects of hypoxia may negatively impact cancer cell viability, in most cases hypoxia
facilitates tumor growth in selective tumor microenvironment niches. The mechanisms of
increased tumorigenic potential of cells exposed to hypoxia have not been fully understood,
but studies have suggested a hypoxic microenvironment may provide a driving force for
genomic instability, which results in resistance to apoptosis and increased invasive capacity
(Bristow and Hill, 2008, Pires et al., 2010). In addition, hypoxia-driven adaptive responses
trigger tumor proliferation and even resistance to anticancer therapy.
Over 55 years ago, Tomlinson and Gray first observed histological patterns of hypoxic
cells residing at the edge of the oxygen diffusion limit from functional blood vessels (no more
than 180 µm diameter away) and further postulated oxygen diffusion as a major factor
influencing effectiveness of radiation therapy (Thomlinson and Gray, 1955). Their finding
has led to intense research on radiobiology in cancer treatment. At present, it is well-known
that the intratumoral oxygen level is arguably the most important determinant of tumor
response to radiation therapy. This is because radiation therapy works by causing DNA
7

damage in tumors through free hydroxyl radicals forming from the ionization of water.
Oxygen, as a potent radiosensitizer, reacts with these free radicals and mediates radiationinduced cytotoxicity (Fig. 3). Therefore, a hypoxic environment decreases radiosensitivity of
tumor cells and results in increased resistance to radiation damage in hypoxic tumor cells
than those in normoxia (Harrison et al., 2002, Jordan and Sonveaux, 2012). Not only does
oxygen level affect radiation therapy, the presence of oxygen is also associated with the
efficacy of chemotherapy. Poorly developed blood vessels in intratumoral hypoxic areas limit
the delivery of circulating chemotherapeutic agents to tumors. Therefore, control of tumor
hypoxia by increasing the oxygenation or decreasing hypoxic fraction of tumors has great
clinical implications in cancer therapeutics. One potential strategy is to target Hypoxia
Inducible Factor (HIF-1), a key regulator responsible for cellular adaptation to hypoxia.
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radiation-induced cytotoxicity. Hypoxic tumor areas
area
Figure 3.. The role of oxygen in radiation
have been found to be very resistant to radiation damage and largely influence therapeutic
outcome of radiotherapy. Oxygen is involved in the stabilization of the DNA damage caused
by ionizing radiations. A) Irradiation induces water ionization and destabilization, leading to
the formation of reactive free radicals. B) These reactive radical species further interact with
other molecules within the body and form new reactive oxygen species (ROS). C,D) Among
ROS, hydroxyl radicals are the most potent mutagens to mediate DNA damage with
oligonucleotide strand breaks. Th
The
e initial DNA damage is readily reversible. However, the
present of oxygen can stabilize DNA damage through oxidative reaction and form DNA
peroxides, which require intensive repair mechanism. This figure was adapted from
Bénédicte
e F. Jordan and Pierre Son
Sonveaux,, Front. Pharmacol., (2012). doi:
10.3389/fphar.2012.00094.
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1.4 Hypoxia Inducible Factor - 1 (HIF-1)
The oxygen homeostasis is regulated by the transcription factor HIF-1, which was first
described by Semenza and co-workers in 1992. The HIF-1 was first discovered by its
induction of erythropoietin (EPO) upon hypoxia which stimulates erythrocyte proliferation
and increases the O2 carrying capacity of the blood (Goldberg et al., 1988, Semenza et al.,
1991). Currently, there are six known members in the human HIF family, which consists of
three α subunits (HIF-1α, HIF-2α and HIF-3α) and three β subunits in (HIF-1β, HIF-2β and
HIF-3β) (Fig. 4). The structures of α subunits share some feature domains: basic helix-loophelix (bHLH), two internal homology Per-Arnt-Sim (PAS) domains, a von Hippel-Lindau
(pVHL) oxygen dependent degradation domain (ODD), and N-terminal and C-terminal
transactivation domain (N-TAD and C-TAD; except HIF-3α that lacks C-TAD). In contrast,
HIF’s β subunits contain bHLH and PAS domains, but no ODD, N-TAD or C-TAD. The bHLH
domain is important for mediating DNA binding and HIF-α/β heterodimerization, while two
PAS domains act as secondary interfaces for HIF-α/β recognition, dimerization and
stabilization (Kenneth and Rocha, 2008). Therefore, bHLH-PAS region serves as a
potential and selective target for development of small molecular disruptors of HIFα/β heterodimerization.
All three HIF α isoforms can dimerize with HIF-1β, but have more limited ability to bind
with HIF-2β. When HIF α and β subunits dimerize, the HIF-α/β complex becomes a
functional transcriptional factor. At present, the specific roles of HIF-α/β heterodimers have
not been fully understood (Drutel et al., 1996, Maltepe et al., 2000, Powell and Hahn, 2002)
but extensive studies have been conducted to understand the HIF-1α/β heterodimer. These
studies have demonstrated that HIF-1α/β is a master transcription factor responsible for
cellular adaptation to hypoxia and regulates the expression of several genes involved in
tumor development, such as angiogenesis and glycolysis (Bardos and Ashcroft, 2005, Ziello
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et al., 2007, Semenza, 2007b). Therefore, disruption of HIF-1α/β dimerization could be an
effective approach to block hypoxia-induced tumorigenesis and prevent resistance to
anticancer therapies. To these ends, in this dissertation, we specifically focus on developing
HIF-1α/β heterodimerization inhibitors that may be utilized as anti-cancer drugs.
HIF-1α is a 120 kDa bHLH-PAS protein. The stability and activity of HIFα are tightly
regulated by oxygen-dependent degradation through its post-translational modifications
such as hydroxylation, ubiquitination, acetylation, and phosphorylation. Under normoxic
conditions, HIF-1α is hydroxylated at conserved proline residues (Pro-402 and Pro-564) by
prolyl hydroxylase, which rapidly leads to its recognition by pVHL/Elongin B and C/Cul2
ubiquitin E3 ligase for ubiquitination and further degradation by proteasome within minutes
(9-11). Under hypoxic conditions, the lack of oxygen inhibits prolyl hydroxylase activity and
prevents HIF-1α degradation. The expression of HIF-1α can usually be detected after 30
minutes of exposure to hypoxia (1-2% O2) and peaks between 4-8h under hypoxic
conditions. Stabilized HIF-1α then translocates into the nucleus and forms a heterodimeric
transcriptional factor with HIF-1β (Fig. 5). HIF-1β is constitutively expressed and found
abundantly in the nucleus regardless of oxygen tension. The now functional HIF-1α/β
transcription factor binds to 50-base pair cis-acting hypoxia-response elements (HREs; 5’RCGTG- 3’) in cellular genome and activates the HIF-1 driven gene transcription in hypoxic
cancer cells (15).
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Figure 4. Human HIF family HIF
HIF-1α, HIF-2α, HIF-3α and HIF-1β. The structure of HIF-α
HIF
isoforms share four domains: basic helix
helix-loop-helix
helix (bHLH), two internal homology Per-ArntPer
Sim (PAS) domains, a von Hippel
Hippel-Lindau
Lindau (pVHL) targeted oxygen dependent degradation
domain (ODD), and N-terminal
terminal and C
C-terminal transactivation domain (N-TAD
TAD and C-TAD;
C
except HIF-3α without C-TAD).
TAD). HIF
HIF-1α and HIF-2α also each contains a nucleus
translocation signal (NLS) for transferring into nucleus. Meanwhile, HIF
HIF-β
β contains bHLH
and PAS domains,
ains, but no ODD, N-TAD and C-TAD. The figure was modified and adapted
from Kenneth and S. Rocha, Biochem. J. (2008) 414, 19
19–29.
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HIF-1α. In normoxia, HIF-1α is hydroxylated at proline residues
Figure 5.. Regulation of HIF
(Pro-402 and Pro-564)
564) by HIF prolyl
prolyl-hydroxylases,
hydroxylases, allowing recognition and ubiquitination by
the pVHL/Elongin B and C/Cul2 ubiquitin E3 ligase and leading HIF
HIF-1α to rapid degradation
by the proteasome. Under hypoxic condit
conditions,
ions, the lack of oxygen prevents HIF-1α
HIF
being
hydroxylated and reduces the degradation process. In response, stabilized HIF-1α
HIF
then
translocates into the nucleus and forms a heterodimeric with HIF
HIF-1β. HIF-1α
1α/β heterodimers
then served as a transcriptional activator binding to HIF-responsive
responsive elements (HREs) and
regulating the expression of multiple genes involved in tumor metabolism and
vascularization. The figure was modified and adapted from Veronica A. Carroll and Margaret
Ashcroft, Expert Reviews in Mol
Molecular Medicine, (2005) Vol.7, Issue 6.
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1.5 Hypoxia related pathways
In response to hypoxia, HIF-1α/β serves as a master transcriptional factor, which
interconnects with several essential pathways with varying functions to maintain oxygen
homeostasis. Hundreds of genes are transcriptionally regulated by HIF-1α/β via binding to
the HRE consensus site in their promoter regions (Semenza et al., 1991, Elvidge et al.,
2006). However, HIF-1α/β binding is detected only in genes with increased expression. HIF1-dependent decrease in transcription occurs via indirect mechanisms, which include HIF-1dependent expression of transcriptional repressors and microRNAs (Yun et al., 2002,
Kulshreshtha et al., 2007).
Using a comprehensive DNA microarrays analysis, it has recently been found that at
least 2.6% of human genes (total 22283 genes studied) are regulated by hypoxia in a HIF1α/β dependent manner in arterial endothelial cells, directly or indirectly (Manalo et al.,
2005). Moreover, this study also demonstrated a large group of genes regulated by hypoxia
involved in cell growth/proliferation, signal transduction, oxidoreduction, mitochondrial and
ribosomal

biogenesis,

RNA

binding/metabolism,

protein

ubiquitination/proteasomal

degradation and transcription activation (Fig. 6).

1.6 HIF-1α/β related pathway in cancer
HIF-1α/β is a major regulator of critical processes in malignancy such as angiogenesis,
apoptosis, proliferation, invasion and metabolism. Many studies have suggested that an
increased HIF-1α/β level is highly associated with cancer progression and metastasis
(Sumiyoshi et al., 2006, Volm and Koomagi, 2000, Zhong et al., 1999).
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For instance, stabilized HIF-1α/β stimulates the production of vascular endothelial
growth factor (VEGF) and other hypoxia-induced angiogenic cytokines (such as FGF, and
TGF), that promote endothelial cell proliferation, increase vascular permeability and cell
migration. The formation of new blood vessels, known as neovascularization or
angiogenesis, is a critical step in the multistage process of tumor metastasis (Olenyuk et al.,
2004).
HIF-1α/β is also a key mediator in many metabolism pathways, and is responsible for
the upregulation of glycolytic enzymes to increase energy consumption. Expressions of
glucose transporter 1 (GLUT-1), hexokinase 2 (HK2) and other glycolytic enzymes are
elevated by active HIF-1α/β to promote glucose use in cancer cells during hypoxia (Song et
al., 2009, Wood et al., 1998, Denko, 2008).
Moreover, HIF-1α/β is important for hypoxic stimulated epithelium-mesenchyme
transition (EMT) in tumor invasion by suppressing E-cadherin expression and enhancing
matrix metalloproteinase-2 (MMP2) and collagen I (Krishnamachary et al., 2006, Higgins et
al., 2007, Jing et al., 2013). Many HIF-1α/β target genes, such as insulin-like growth factor 2,
IGF-binding protein 1, 2 and 3, have pro-survival effects by stimulating cell proliferation
under reduced oxygen availability (Vaupel, 2004). Although most of HIF-1α/β targeting
genes promote cell survival, apoptosis can also be initiated by HIF-1 in certain situations like
prolonged chronic hypoxia (Carmeliet et al., 1998). The HIF-1α/β regulated pro-apoptotic
gene BNIP3 is found to be overexpressed in perinecrotic regions of the human tumors
(Koop et al., 2009). HIF-1α/β has also been shown to induce cell cycle arrest to decrease
cell proliferation rates in hypoxia, which allows cells in stressful microenvironment to slow
their growth and conserve energy for survival (Koshiji et al., 2004, Goda et al., 2003).
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With these essential involvements of HIF-1α/β in tumor vascularization and
metabolism, HIF-1α/β has become an important target for the development of anti-cancer
drugs. In fact, many researchers have suggested that inhibitors of HIF-1α/β may pose better
potential to limit cancer progression than using inhibitors of its downstream gene products
such as VEGF (Semenza, 2007a, Melillo, 2006, Welsh and Powis, 2003).
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Figure 6. HIF-1-regulated
regulated genes play essential roles in adaptive mechanisms to
hypoxia. This figure was modified and adapted from Gregg L. Semenza,, Nature Reviews
Cancer 3, 721-732 (October
October 2003). Copyright permission
ermission was obtained from Nature
Publishing Group.
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1.7 Imaging of Hypoxia
Measuring hypoxia is critical in determining the aggressiveness of tumor and
assessing the effectiveness of anti-cancer treatments. As a result, numerous invasive and
noninvasive approaches have been developed to measure hypoxic regions in tumors,
including polarographic electrodes, magnetic resonance imaging (MRI), positron emission
tomography (PET), single-photon emission computed tomography (SPECT) and optical
imaging (fluorescence and bioluminescence) (Tatum et al., 2006, Sun et al., 2011).
The most promising imaging method to measure hypoxia would be using a
radiolabeled probe that competes directly with intracellular O2. PET imaging with

15

O2

inhalation can provide accurate measurements of oxygen tension in tissues (Krohn et al.,
15

2008, Serganova et al., 2006). However, the short half-life of

O2 (about 2 minutes) and

high cost hinder this approach in the clinical setting. The first clinical study to image hypoxia
in PET was using 2-nitroimidazole, which is a bioreductive compound that undergoes a
reduction reaction by hypoxia-induced nitroreductase and is then trapped in hypoxic tissues
(Chapman, 1984, Lee and Scott, 2007). The covalent binding of a 2-nitroimidazole-protein
adduct can be detected with specific antibodies or imaged by labeling PET radionuclides,
such as

18

F and

124

I, or with single-photon emitters, such as

123

I and

99

mTc for SPECT. The

commonly used nitroimidazoles derivatives are EF5, pimonidazole and misonidazole
(Grunbaum et al., 1987, Martin et al., 1992). So far,

18

F-FMISO is the most robust and

common radiopharmaceutical to quantify hypoxia in clinic. The other alternative PET
bioreductive agent for measuring hypoxia is radioactive copper (60Cu,

61

Cu,

62

Cu or

64

Cu)

with diacetyl-bis(-methylthiosemicarbazone) (Cu-ATSM). It has been demonstrated that
64

Cu-ATSM accumulates more rapidly than

normoxic ratio (O'Donoghue et al., 2005).
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18

F-FMISO and has a greater hypoxic to

Other radiation free approaches utilize MRI to measure hypoxia. However, MRI without
exogenous contrast, such as blood oxygen level dependent (BOLD) MRI or MRS for lactate
or NADH/NADPH imaging, are measuring a downstream consequence of hypoxia and often
cause a time delay in re-oxygenation. Some oxygen-sensitive MR reporter agents, generally
based on perfluorocarbons (PFCs), have also been developed for
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F MR oximetry. These

agents showed great potential with sequential measurements over time and provided robust
detection with nanomolar (nM) sensitivities (Lemaire et al., 2013, Stoll et al., 2012, Mason et
al., 2010). These MR hypoxia imaging techniques are currently developed in animal studies,
but starting to be established in human tumor research.
The bioluminescent and fluorescent imaging technologies possess several strong
advantages for exploring the detailed molecular mechanisms of hypoxia. Although
bioluminescent and fluorescent imaging technologies are not practiced in the clinic yet, they
serve as great tools for preclinical studies. In this dissertation, we utilized bioluminescence
imaging as the molecular imaging modality of choice. Therefore, greater detail and more
background of bioluminescence imaging will be covered in the following subsection.

1.7.1 Bioluminescent imaging in hypoxia
Bioluminescence is characterized as a process of light emission from a living
organism. Bioluminescence can also be utilized for noninvasive imaging studies to observe
ongoing biological processes in small laboratory animals. The light-producing chemical
reaction is catalyzed by the luciferase enzymes in certain insects, marine species and
bacteria (Photorhabdus luminescens and Vibrio fischeri) (de Wet et al., 1987). The most
commonly used luciferases in research are derived from the North American firefly (Photinus
pyralis) and the sea pansy (Renilla reniformis). The luciferase enzymes start their catalytic
competence immediately after being released from the ribosome, without further post19

translational processing, thus providing instantaneously enzymatic activity. Using firefly
luciferase employed in this dissertation as an example, firefly luciferase catalyzes the
chemical reaction through two steps:

•

D-luciferin + ATP → luciferyl adenylate + pyrophosphate

•

luciferyl adenylate + O2 → oxyluciferin + AMP + light

The wavelengths of light emitted through firefly luciferase reaction are typically in
green (λmax = 550 nm) to yellow (λmax = 570) part of the spectrum, depending on the
luciferase structure or its microenviroment (DeLuca and McElroy, 1974, Viviani et al., 2005).
Researchers have utilized these luminescent proteins in genetic engineering for numerous
purposes. Luciferase genes can be transfered into cells or even experimental laboratory
animals and are widely used as reporters to assess transgene expression activity in vitro
and in vivo. To be used as a genetic reporter, the luciferase gene is regulated by the
promoter sequence of a gene of interest. Thus, the level of that gene transcription is
proportional to the light intensity produced by the luciferase.
So far, a few bioluminescent imaging methods have been developed to image
hypoxia via measuring HIF-1 transcriptional activity. Payen et al. first proposed the idea
using HRE sequences coupled with reporter genes, such as luciferase or GFP, to enable
imaging HIF-1 transcriptional activity (Payen et al., 2001). In 2004, Serganov et al.
demonstrated in vivo small animal imaging of HIF-1 transcriptional activity using GFP/tk
reporter under control of 8×HREs (Serganova et al., 2004).

1.8 HIF-1 inhibitors in cancer
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Hypoxia has been recognized as an essential player in tumor microenviroment and a
prognosis marker to anti-cancer treatment. Since HIF-1α is a master regulator in response
to hypoxia, the development of HIF-1 inhibitors has become the focus of several research
groups. In the following, the current discovery and characterization of small molecule
inhibitors for targeting HIF-1 pathway will be covered.
To date, considerable efforts have been devoted to the development of HIF-1 inhibitors
that reduce HIF-1α mRNA or protein levels, HIF-1 DNA binding, or HIF-1 activation of
transcription (Table. 1). Among them, agents that decrease HIF-1α protein levels can be
further classified by their ability in inhibiting the rate of HIF-1α translation or promoting the
rate of HIF-1α degradation.

A. Small molecular inhibitors of HIF-1α protein levels
The PI3K/Akt/mTOR signaling pathway, which promotes cell proliferation and reduces
apoptosis by regulating protein synthesis, is often overactive in many cancers. This
prototypic survival pathway also plays a major role in upregulation of HIF-1α protein
synthesis in most human cancer cell lines. With the use of PI3K specific inhibitors:
wortmannin and LY294002, they could downregulate insulin- and epidermal growth factorinduced expression of HIF-1α in prostate carcinoma cell lines PC-3 and DU145 (Jiang et al.,
2001). A clinically used mTOR inhibitor, rapamycin, has been proven to decrease HIF-1α
protein expression in cells (Hudson et al., 2002). Its chemical derivative inhibitor, RAD-001,
also demonstrated attenuation of most HIF-1 target gene expressions in the prostates of
AKT1 expressing mice (Majumder et al., 2004). The other mTOR inhibitor, CCI-779, showed
inhibition of cell proliferation and HIF-1α translation in VHL-mediated renal cell carcinoma
(Thomas et al., 2006). EZN-2968 is an RNA antagonist which specifically binds to HIF-1
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mRNA and inhibits the expression of HIF-1α mRNA in DU-145 human prostate and
glioblastoma cells (Greenberger et al., 2008).
The chaperone HSP90 interacts with HIF-1α and is required for HIF-1α protein stability.
Inhibitors of HSP90, such as geldanamycin (GA) and its derivatives 17-allylamino-17demethoxygeldanamycin

(17-AAG)

and

17-dimethylaminomethylamino-17-

demethoxygeldanamycin (17-DMAG), are naturally occurring benzoquinone ansamycin
antibiotics. These compounds have been demonstrated to interfere with Hsp90 function by
competing with its ATP binding site, and inducing ubiquitination and proteasomal
degradation of HIF-1α in VHL-independent renal and prostate cancer cells (Isaacs et al.,
2002, Mabjeesh et al., 2002, Porter et al., 2009, Drysdale et al., 2006). Of note, both 17AAG and 17- DMAG are currently being tested in clinical trials. Other epigenetic studies
have demonstracted that inhibitors of histone deacetylases (HDACi) can suppress HIF-1α
protein expression via increasing its acetylation-dependent degradation. The Sirtuin 1
(SIRT1)

deacetylase

inactivates

HIF-1α

by blocking

HIF-1α-p300/HIF-α-CBP

and

consequently inhibited HIF-1 transactivation of downstream target genes (Chen and Sang,
2011). Other novel inhibitors, such as YC-1 and PX-478, have also been identified to inhibit
HIF-1α protein accumulation and hypoxic induced HIF-1 transcriptional activity in a variety of
cancer cell lines (Semenza, 2006, Schwartz et al., 2009, Schwartz et al., 2011).
Using an engineered U251 human glioma cell-based high-throughput screen system
(U251-HRE), a large chemical library was explored for the identification of agents that inhibit
HIF-1 activity, three of which were closely related to camptothecin analogues and DNA
topoisomerase I inhibitors (Rapisarda et al., 2002). Topotecan was one of the camptothecin
analogues which showed inhibition of hypoxia induced HIF-1α accumulation and HIF-1dependent gene expression at a low nanomolar concentration in U251 cells. Although
mechanisms of camptothecin analogues in suppressing HIF-1 protein expression have not
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been fully delineated, two other camptothecin analogues, topotecan and irinotecan, have
gone through clinical trials and are currently used in cancer therapy.
RNA interference approaches using small interfering RNA (siRNA) or short hairpin
RNA (shRNA) targeting HIF-1α have been developed recently. These RNA oligos were
designed using the coding sequence of HIF-1α for specific targeting motifs. Several studies
have demonstrated that the siRNAs can effectively suppress HIF-1α expression, inhibit HIF1 related signal transduction, increase cell apoptosis, and enhance sensitivity to
chemotherapeutic drug (Hanze et al., 2003, Kessler et al., 2010, Yu et al., 2004).The
application of siRNA in vivo studies also showed potential anti-tumor efficacy in vivo mouse
models (Liao et al., 2012, Jiang et al., 2007) Noteworthy, treatment with siRNA or antisense
oligonucleotides suppressed both HIF-1α expression at both mRNA and protein levels
(Zhang et al., 2004).

B. Small molecular inhibitors of HIF-1 DNA binding
In this category, these inhibitors prevent HIF-1 binding to HREs and suppress
transactivation of HIF-1 target genes. For example, Echinomycin binds to DNA of the HIF-1
recognition sequence 5’-CGTG-3’ and inhibits HRE-mediated transcriptional activity in U251
glioma cells (Van Dyke and Dervan, 1984, Kong et al., 2005). Other inhibitors of HIF-1 DNA
binding include polyamides (Olenyuk et al., 2004), and DJ12 (Jones and Harris, 2006).

C. Small molecular inhibitors of HIF-1 transcriptional activity
Another mechanism of HIF-1 inhibition is at the level of transactivation. Bortezomib
was the first therapeutic proteasome inhibitor to be tested in humans. It elevates HIF-1α
protein levels by blocking its degradation and specifically inhibits HIF-1α C-TAD despite the
activation of HIF-1α coactivators p300 (Kaluz et al., 2006). In addition, the antifungal drug
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amphotericin B was found to inhibit HIF-1 transcriptional activity by promoting interaction of
HIF-1α C-TAD with FIH-1 (Yeo et al., 2006).

D. Small molecular inhibitors of HIF-1 dimerization
HIF-1α/ β dimerization is mediated by the bHLH and PAS domains in N-terminal end of
HIF-1α and HIF-1β (Semenza et al., 1997). Although the structural and functional map of
HIF-1 has been known since 1997, the development of specific small molecular inhibitors
targeting this mechanism has long been attractive, yet elusive. Recently, through the
screening from a FDA approved clinical trials drug library using a cell-based split-luciferase
screening assay, acriflavine (ACF) was found to act directly on the HIF-1α/β dimerization
(Lee et al., 2009). ACF, a commonly used antimicrobial agent discovered almost 100 years
ago, is a mixture of 3,6-diamino-10-methylacridinium chloride (trypaflavin) and 3,6diaminoacridine (proflavine). The study showed that ACF interacts with PAS-B subdomain of
HIF-1α or HIF-2α, thus blocking the binding with HIF-1β. In addition, ACF treatment
suppressed HIF-1 transcriptional activity and led to inhibition of tumor growth and
vascularization in mice bearing prostate cancer xenografts. However, other studies also
indicated ACF works as a topoisomerase I and II inhibitor to trigger permanent DNA damage
and cell death in several cancer models (Hassan et al., 2011, Salerno et al., 2010). The
finding that ACF also works as a topoisomerase I and II inhibitor seems in line with its HIF1α inhibition. Topoisomerase I inhibitors, such as camptothecin mentioned above, limit DNA
transcription and have strong suppressive effect on hypoxia induced HIF-1α accumulation in
cancer cells (Xia et al., 2012, Rapisarda et al., 2002). The study conducted by Semenza’s
group, however, did not observe decreased HIF-1α level by ACF at the concentration used
to inhibit HIF-1 dimerization. Overall, in previous preclinical models, ACF showed short
pharmacokinetic half-life and reached peak plasma concentrations well above the IC50
values for anti-cancer activity (Song et al., 2005, Kim et al., 1997). With this background,
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further clinical development of ACF as an anti-cancer drug seems promising for its dual
inhibition of HIF-1 dimerization and HIF-1α expression. Nevertheless, the mechanisms of
action of ACF remain to be fully elucidated.
In conclusion, none of the presently available inhibitors appears to disrupt the HIF-1
pathway as an exclusive target. The design of more specific HIF-1 targeting agents is likely
to become the future research priority (Semenza, 2007a, Mooring et al., 2011, Yewalkar et
al., 2010, Narita et al., 2009, Tan et al., 2005, Park et al., 2006b). Blocking the dimerization
domain of HIF-1α/HIF-1β disables its ability to form HIF-1α/β heterodimers and negates HIF1 activated adaptive reactions involved in tumor development. Since the dimerization is
essential for a fully functional HIF-1 transcriptional factor, we proposed to explore novel
inhibitors of HIF-1α/β heterodimerization as the major goal of this work.
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Table 1: HIF-1 inhibitors and their mechanism of action

Mechanism and Target of HIF-1 inhibition

Agent
GL331, siRNA, shRNA

I. Decreased HIF-1α mRNA levels:
II. Decreased HIF-1α protein levels
A. PI3K-AKT-mTOR

Wortmannin, LY294002, CCI-779,
rapamycin, RAD-001, EZN-2968

B. HSP90

GA, 17-AAG, 17-DMAG, apigenin

C. Histone deacetylases

SIRT1, LAQ824, FK228

D. Topoisomerases

Topoisomerase I : topotecan, irinotecan

E. Cyclin-dependent kinases

flavopiridol

F. Microtubule targeting agents

2-methoxyestradiol, epothilone B,
taxotere

G. Unknown targets

YC-1, PX-478, berberine, pseudolaric
acid B, bisphenol A, manassantin B1,
manassantin A, 4-O-methylsaucerneol,
laurenditerpenol, 103D5R

III. Decreased binding of HIF-1 to DNA
echinomycin, polyamides,DJ12
IV. Decreased HIF-1-mediated transactivation
A. Proteasome:
bortezomib
B. Histone deacetylases:

SAHA/vorinostat, trichostatin A

C. P300:

chetomin

D. Unknown:

amphotericin B

V. Decreased HIF-1α and HIF-1 β dimerization acriflavine
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1.9 Specific aims of the project
To initiate hypoxia adaptive responses in cancer, HIF-1α and HIF-1β heterodimerize
and serve as a transcriptional activator to hundreds of target genes involved in tumor
metabolism and vascularization. In an attempt to improve hypoxia-selective cytotoxicity,
disruption of HIF-1α/β dimerization using small molecules is considered to be a promising
therapeutic strategy. Our ultimate goal for this dissertation was to discover selective and
effective inhibitor for HIF-1 dimerization. The long-term goal of the study would be to
translate our therapeutic agents into clinic and benefit cancer patients.
To achieve these goals, the following specific aims were proposed:
Aim 1: To Develop and Optimize a Reporter System for Bioluminescence Imaging of
HIF-1α/HIF1β Heterodimerization
Aim 2: To Conduct High-Content Screening of Inhibitors of HIF-1α/HIF1β Dimerization
in Cellulo and to Explore Structure-Activity Relationships
Aim 3: To Access Selected Agents as Inhibitors of HIF-1-mediated Transcriptional
Activity
Aim 4: To Evaluate Therapeutic Efficacy of Selected Inhibitors in Tumor Xenograft
Bearing Mice
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Chapter 2: Materials and Methods
Cell Culture
HEK293T and U87 glioma cells (American Type Culture Collection, Manassas, VA)
were maintained in Dulbecco’s modified Eagle’s medium/F-12 medium supplemented with
10% fetal calf serum (Gibco, Carlsbad, CA) and 100 µg/mL normaxin (InvivoGen, San Diego,
CA). Cells grew in a 37°C incubator with 5% CO2.

Construction of HIF-1 Heterodimerization Imaging lentiviral Vectors
DNA sequences of the human bHLH-PAS domain of HIF-1α (residues 12-396) and
HIF-1β (residues 11-510), and the N-terminus (NL; residues 1-437) and C-terminus (CL;
residues 438-554) of firefly luciferase were prepared using PCR. These DNA sequences
were then inserted into donor vectors (pDONR222 or pDONR222) via a Gateway BP
reaction (Invitrogen, Carlsbad, CA). Following a Gateway LR reaction, we obtained two
different orientations of HIF-1α12-396 linking with N- terminal halves of luciferase in pLVDL301
vector (pLVDL 301-NL-HIF-1α12-396 and pLVDL 301-HIF-1α12-396-NL), and two different
orientations of HIF-1β11-510 linking with C- terminal halves of luciferase in pLVDL312 vector
(pLVDL 312- CL-HIF-1β11-510 and pLVDL 312 -HIF-1β11-510- CL) (Fig. 7). The gateway
recombination cloning technique was based on bacteriophage lambda site-specific
recombination system which facilitates the integration of lambda into the E. coli chromosome
and the switch between the lytic and lysogenic pathways (Arkin et al., 1998). The method
prevents traditional restriction enzyme based cloning limitations, accurately shuttles target
DNA inserts to our vectors, and highly facilitates the creation of our DNA vectors. Vector
pLVDL301 was specifically designed to contain two gateway cassettes, attR1 and attR2
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sites, with downstream IRES to control eGFP gene expression. Whereas, Vector pLVDL312
also contains two gateway cassettes with IRES controlled mKate expression. We decided to
use pLVDL301 as the destination vector (eGFP) for HIF-1α reporter components and
pLVDL312 (mKate) for HIF-1β reporter components.
In the following experiment to verify its functionality, HEK293T cells were plated at 7080% confluence on the day of transfection. Cells were transfected (1:1) with four plasmid
vectors alone, two different plasmid combinations, or single plasmids with nonsense-NL/CL.
Volumes of Lipofectamine 2000 (Invitrogen) were used as recommended by the
manufacturer for DNA delivery. The efficiency of plasmid transfection was assayed 48 h
later via fluorescence using a microplate reader (Tecan, Männedorf, Switzerland). D-luciferin
was added to the cell medium to perform bioluminescent imaging (BLI) by 1 min of photon
counting using an IVIS 200 Series imaging system (Caliper Life Sciences, Hopkinton, MA).
All BLI measurement were performed in triplicate. Relative light-unit readings were
normalized by mKate fluorescence counts.
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Figure 7. Construction of HIF-1α12-396 and HIF-1β11-510 reporter vectors.. Vector maps of
the HIF-1α12-396/N-terminal halves of luciferase (a,b) and HIF-1β11-510/C-terminal
terminal halves of
luciferase fusion proteins(c,d).
s(c,d). HIF-1α12-396 was cloned into the pLVDL 301 dual destination
vector with eGFP reporter, cre
creating pLVDL 301-NL-HIF-1α12-396 and pLVDL 301-HIF-1α
301
12-396NL. HIF-1β11-510 was cloned into the pLVDL 312 dual destination vector with mKate reporter,
creating pLVDL 312- CL-HIF
HIF-1β11-510 and pLVDL 312 -HIF-1β11-510-CL.
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Production of Lentivirus for generating U87 HIF-1 Heterodimerization Reporter Cells
Four different lentiviral stocks were produced by cotransfecting previously developed
HIF-1 reporter lentiviral vectors and ViraPower Packaging Mix (Invitrogen) into HEK 293T
packaging cells. The virus was harvested from the cell culture medium 24, 48, and 72 h after
transfection. After filtering the collected medium through 0.22-µm filters, the virus was
concentrated via centrifugation at 3500 rpm for 30 min at 4°C. The concentrated lentiviral
stocks were then stored at -80°C for later use.
After production of the lentiviral stocks, U87 cells were seeded in six-well culture
dishes at 90% confluence and transduced with different pairs of HIF-1α and HIF-1β
reporters using lentivirus stocks (1:1, respectively). The culture medium was supplemented
with 2 µg/mL hexadimethrine bromide (Polybrene; Sigma, St. Louis, MO) at the time of
transduction. At 24 h after transduction, the culture medium containing the virus was
removed and replaced with fresh medium.

Flow Cytometry and Protein Expression Analysis of Transduced U87 Reporter Cells
The transduced U87 cells were culture-expanded and analyzed for expression of the
HIF-1 reporter using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) after a
week of transduction. The cells were collected via centrifugation at 1500 rpm, and
resuspended into 500 µl PBS. The coexpression of the reporter genes (eGFP and mKate)
was analyzed using a 488- and 620-nm excitation laser, respectively. 100,000 events were
collected each time, and the percentage of cells exhibiting dual eGFP and mKate
fluorescence was determined using FlowJo X program (Ashland, OR).
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Selection of Stably Transduced U87 Reporter Cells
Stably expressed U87/NL1α/CL1β reporter cells were selected using a BD FACSAria
cell sorter (BD Biosciences) for future screening experiments. Only dual pLVDL 301-NL-HIF1α12-396 and pLVDL 312- CL-HIF-1β11-510 expressed cells within a narrow region spanning
about 103 on the eGFP and mKate expression scale of a histogram plot were collected. The
sorted U87/NL1α/CL1β cells were replated back to 96-well plates at the concentration of 20
cells/well. After a week of growing, each well was examined for dual eGFP and mKate
fluorescence under a microscope. The U87/NL1α/CL1β cells with the most homogenous
expression of dual reporters were dispersed into new 12-well plates for further expansion.
These stably transduced U87/NL1α/CL1β cells were later used in the drug screening
experiments.

Competitive HIF-α/β Protein-Binding Assay
U87/NL1α/CL1β cells were seeded at 5 x 104 cells per well in a 24-well plate,
incubated for 12 h, and transfected with HIF-1α, HIF-1β, or control DNA. BLI and fluorescent
imaging of U87 reporter cells were performed at 24 and 48 h after transfection. Also, a WST1 cell viability test (Cayman Chemistry, Ann Arbor, MI) was performed in each group of
experiments after the imaging. All experiments were done in triplicate.

Hypoxia Chamber-Induced Endogenous HIF-1α Competition Assay
U87/NL1α/CL1β cells were seeded at 5 x 104 cells per well in a 24-well plate and
incubated for 12 h. To induce hypoxia, cells were placed in a modular incubator chamber
(Billups-Rothenberg Inc., Del Mar, CA) and flushed with a mixture of gas consisting of 5%
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O2, 5% CO2, and balance N2. The chamber was then sealed and incubated at 37°C. Cells
under normal culture conditions were used as controls. BLI, fluorescent imaging, and WST-1
cell viability testing were performed 24 and 48 h after treatment. Different groups of cells
were collected and lysed for later western blot analysis.

High-Throughput Drug Screening In Vitro
Stably transduced U87/NL1α/CL1β cells were preseeded in 96-well plates at 4 x 104
cells per well. A library of 41 compounds, previously reported to inhibit HIF-1 activity, or a
vehicle (0.1% dimethyl sulfoxide [DMSO]) were added to each well for 24 h. The cells were
imaged and analyzed using BLI with an IVIS 200 Series system via 1-min photon counting
and fluorescence with a Tecan microplate reader. All BLI results were analyzed using Living
Image software program (Caliper Life Sciences, Hopkinton, MA). All the experiments were
done in triplicate. If the drug treatment resulted in a significant decrease in the BLI signal,
the cells were further analyzed using the WST-1 cell viability test.

Chemical Reagents and Instrumentation
Reagents and solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI)
and used without further purification. Thin-layer chromatography was performed with
precoated Kieselgel 60 F254 aluminum plates (Merck, Darmstadt, Germany). Proton,

13

C,

and 19F nuclear magnetic resonance (NMR) spectra were recorded using a Bruker 300-MHz
spectrometer (Bruker, Rheinstetten, Germany) with tetramethylsilane as an internal
reference at The University of Texas MD Anderson Cancer Center. High-resolution mass
spectra for newly synthesized compounds were obtained with a Bruker BioTOF II mass
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spectrometer (Bruker, Rheinstetten, Germany) at the University of Minnesota using
electrospray ionization. Neutral proflavine was prepared from 3,6-diaminoacridine
hemisulfate (Aldrich Chemical, Milwaukee, WI), which was dissolved in water, and 10%
NH4OH was added to the solution until the pH was 8 under vigorous stirring. The solution
was then filtered, washed with water, and dried to afford neutral proflavine. Compounds 1, 3,
4, and 5 were purchased from Aldrich Chemical Co. and used as received. Compound 2
was prepared using a reported procedure for similar compounds. The detailed synthesis of
other compounds will be covered in the following section.

Chemistry Synthesis
General procedure A: reaction of proflavine with anhydrides for synthesis of compounds 68 as reported previously.
A solution of anhydride (3 eq.) was added dropwise to proflavine (1 mmol, 1 eq.) in
pyridine (6 mL) and triethylamine (0.5 mL) at 50°C under N2 atmosphere with vigorous
stirring. Stirring was continued for 1 h at 80°C. The mixture was then poured into water
(80 mL). The obtained precipitate was filtered, washed with water, dried, and recrystallized
using ethanol to yield the corresponding product.
General procedure B: reaction of proflavine with alkoyl chlorides for synthesis of
compounds 9-15
A solution of aroyl chloride (3 eq.) in acetone (10 mL) was added dropwise to
proflavine (1 mmol, 1 eq.) and K2CO3 (10 eq.) in acetone (40 mL) at 0°C under N2 with
vigorous stirring. Stirring was continued for 15 h at room temperature. The mixture was then
poured into a solution of aqueous NaHCO3 (40%, 80 mL). After cooling at 5°C, the obtained
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precipitate was filtered, washed with water, dried, and recrystallized from ethanol to yield the
corresponding product.
General procedure C: reaction of proflavine with aroyl chlorides for synthesis of compounds
16-24 as reported previously.
A solution of aroyl chloride (3 eq.) in acetone (10 mL) was added dropwise to proflavine
(1.43 mmol, 1 eq.) and K2CO3 (10 eq.) in acetone (40 mL), at 0°C under N2 with vigorous
stirring. Stirring was continued for 15 h at room temperature. The mixture was then poured
into water (30 mL) and then a satd. aq. NaHCO3 solution (20 mL). After cooling at 5°C, the
obtained precipitate was filtered, washed with water and then ether (15 mL), and dried to
yield the corresponding product.
Preparation of N,N'-(Acridine-3,6-Diyl)Dicyclopropanecarboxamide (compound 10)
General procedure B: compound 10 was obtained as yellow fluffy powder at a yield of 45%.
1

H NMR: (DMSO-d6): δ 11.43 (s, 2H, NH), 9.56 (s, 1H, H9), 8.85 (s, 2H, H4, H5), 8.35 (d, J =

9.0, 2H, H1,H8), 7.81 (d, J = 9.0, 2H, H2, H7), 2.03 (m, 2H, CH), 0.95 (m, 8H, CH2:
cyclopropyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Dicyclobutanecarboxamide (compound 11)
General procedure B: compound 11 was obtained as yellow powder at a yield of 57%. 1H
NMR: (DMSO-d6): δ 10.45 (s, 2H, NH), 9.13 (s, 1H, H9), 8.67 (s, 2H, H4, H5), 8.15 (d, J = 9.0,
2H, H1,H8), 7.68 (d, J = 9.0, 2H, H2, H7), 2.40-1.80 (m, 14H, CH, CH2: cyclobutyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Dicyclopentanecarboxamide (compound 12)
General procedure B: compound 12 was obtained as yellow powder at a yield of 57%. 1H
NMR: (DMSO-d6): δ 10.91 (s, 2H, NH), 9.37 (s, 1H, H9), 8.80 (s, 2H, H4, H5), 8.25 (d, J = 9.0,
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2H, H1,H8), 7.78 (d, J = 9.0, 2H, H2, H7), 3.00 (m, 2H, CH: cyclopentyl), 2.00-1.50 (m, 16H,
CH2: cyclopentyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Dicyclohexanecarboxamide (compound 13)
General procedure B: compound 13 was obtained as yellow powder at a yield of 57%. 1H
NMR: (DMSO-d6): δ 11.06 (s, 2H, NH), 9.56 (s, 1H, H9), 8.91 (s, 2H, H4, H5), 8.33 (d, J = 9.0,
2H, H1,H8), 7.82 (d, J = 9.0, 2H, H2, H7), 2.55 (m, 2H, CH: cyclohexyl), 2.00-1.62 (m, 11H,
CH2: cyclohexyl), 1.55-1.18 (m, 11H, CH2: cyclohexyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Bis(Adamantanecarboxamide) (compound 14)
General procedure B: compound 13 was obtained as yellow powder at a yield of 57%. 1H
NMR: (DMSO-d6): δ 11.06 (s, 2H, NH), 9.56 (s, 1H, H9), 8.91 (s, 2H, H4, H5), 8.33 (d, J = 9.0,
2H, H1,H8), 7.82 (d, J = 9.0, 2H, H2, H7), 2.55 (m, 2H, CH: cyclohexyl), 2.00-1.62 (m, 11H,
CH2: cyclohexyl), 1.55-1.18 (m, 11H, CH2: cyclohexyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Bis(2,2,3,3Tetramethylcyclopropanecarboxamide) (compound 15)
General procedure B: compound 15 was obtained as yellow powder at a yield of 65%. 1H
NMR: (DMSO-d6): δ 11.06 (s, 2H, NH), 9.56 (s, 1H, H9), 8.91 (s, 2H, H4, H5), 8.33 (d, J = 9.0,
2H, H1,H8), 7.82 (d, J = 9.0, 2H, H2, H7), 2.55 (m, 2H, CH: cyclohexyl), 2.00-1.62 (m, 11H,
CH2: cyclohexyl), 1.55-1.18 (m, 11H, CH2: cyclohexyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Dibenzenesulfonamide (compound 17)
General procedure C: compound 17 was obtained as yellow powder at a yield of 30%. 1H
NMR: (DMSO-d6): δ 11.06 (s, 2H, NH), 9.56 (s, 1H, H9), 8.91 (s, 2H, H4, H5), 8.33 (d, J = 9.0,
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2H, H1,H8), 7.82 (d, J = 9.0, 2H, H2, H7), 2.55 (m, 2H, CH: cyclohexyl), 2.00-1.62 (m, 11H,
CH2: cyclohexyl), 1.55-1.18 (m, 11H, CH2: cyclohexyl).
Preparation of N,N'-(Acridine-3,6-Diyl)Bis(4-(Trifluoromethyl)Benzamide) (compound
19)
General procedure C: compound 19 was obtained as yellow powder at a yield of 65%. 1H
NMR: (DMSO-d6): δ 11.44 (s, 2H, NH), 9.50 (s, 1H, H9), 9.01 (s, 2H, H4, H5), 8.31 (d, J = 9.0,
2H, H1,H8), 8.24 (d, J = 8.1, 4H, Ph), 8.08 (d, J = 9.0, 2H, H2, H7), 7.92 (d, J = 8.1, 4H, Ph).
Preparation of N,N'-(Acridine-3,6-Diyl)Bis(4-Tert-Butylbenzamide) (compound 20)
General procedure C: compound 20 was obtained as yellow powder at a yield of 60%. 1H
NMR: (DMSO-d6): δ 10.73 (s, 2H, NH), 9.06 (s, 1H, H9), 8.78 (s, 2H, H4, H5), 8.16 (d, J = 9.0,
2H, H1,H8), 7.99 (d, J = 8.7, 2H, Ph), 7.95 (d, J = 9.0, 2H, H2, H7), 7.60 (d, J = 8.7, 2H, Ph),
1.35 (s, 18H, t-Bu).
Preparation of N,N'-(Acridine-3,6-Diyl)Bis(3,4-Dimethoxybenzamide) (compound 21)
General procedure C: compound 20 was obtained as yellow powder at a yield of 60%.
1

H NMR: (DMSO-d6): δ 11.22 (s, 2H, NH), 9.55 (s, 1H, H9), 9.01 (s, 2H, H4, H5), 8.41 (d, J =

8.1, 2H, Ph), 8.22 (d, J = 9.0, 2H, H1,H8), 7.88 (d, J = 9.0, 2H, H2, H7), 7.65 (s, 2H, Ph), 7.16
(d, J = 8.1, 2H, Ph).

Structure Activity Relationship of Acridine Analogs
U87/NL1α/CL1β reporter cells were preseeded in 96-well plates at 4 x 104 cells per
well. A list of our developed acridine analogs with side chain derivatization, ACF (10µM,
positive control) or a vehicle (0.1% dimethyl sulfoxide [DMSO]) were added to each well for
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24 h incubation. The cells were analyzed by BLI with an IVIS 200 Series system via 1-min
photon counting and fluorescence imaging with a Tecan microplate reader, and tested for
the WST-1 cell viability assay. All the experiments were done in triplicate.

HIF-1 transcriptional activity reporter assay
C6#4 reporter cells previously developed in our lab were seeded at 1 x 104 per well in
a 96-well plate, incubated for 12 h, and changed new medium with supplement of 100 µM
CoCl2, producing chemically-induced hypoxia (Serganova et al., 2004). After 4 h, the cells
were treated with different concentrations of vehicle, ACF, M-TMCP and D-TMCP for
additional 24 h incubation. Fluorescent imaging was performed with a Tecan microplate
reader to analyze GFP versus DsRed expression. All the experiments were done in triplicate.
The WST-1 cell viability test (Cayman Chemistry, Ann Arbor, MI) was performed in each
treatment group after the fluorescent imaging.

Rapamycin-regulated firefly luciferase complementation cell-based reporter assays
This reporter assay utilized the rapamycin-binding domain (FRB) of the kinase
mammalian target of rapamycin and FK506-binding protein 12 (FKBP) fused with firefly
luciferase

halves,

respectively,

to

develop

rapamycin-regulated

firefly

luciferase

complementation assay (Luker et al., 2004). HEK293T cells were plated to 70-80%
confluence on the day of transfection. HEK-293 cells transfected with (1:1) FRB-NLuc/CLucFKBP (DNA vectors were obtained from Dr. David Piwnica-Worms’s lab at Washington
University School of Medicine). Volumes of Lipofectamine 2000 (Invitrogen) were used as
recommended by the manufacturer for DNA delivery. In this firefly complementation
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construct design, rapamycin induced FRB/FKBP association and reconstituted luciferase
activity in cells. Therefore, the efficiency of plasmid transfection was assayed via BLI 48 h
later after incubation of 50 nM rapamycin for 6 h. Transfected cells were then transferred
into a 12 well plate at 5 x 104 per well, incubated for 6 h, and changed with new medium. For
the first group of experiments, the transfected cells were first incubated with 50 nM
rapamycin for 6 h to reconstitute luciferase, and then treated with or without 10 µM ACF, N3-(2,2,3,3-tetramethylcyclopropane-carboxamide)-6-aminoacridine hydrochloric acid salt (MTMCP) and N,N'-(acridine-3,6-diyl)bis(2,2,3,3-tetramethyl-cyclopropanecarboxamide) (DTMCP) for 24 h to examine the effect of these inhibitors in disrupting luciferase pairs. For the
second group, 10 µM vehicles ACF, M-TMCP and D-TMCP were first added to the cell
medium for 24 h incubation. Then the cells were treated with 50 nM rapamycin for additional
6 h. All BLI were performed by 1 min of photon counting using an IVIS 200 Series imaging
system (Caliper Life Sciences, Hopkinton, MA).

Quantitative real-time reverse-transcription PCR (qRT-PCR)
U87 WT cells were incubated under normoxia or hypoxia in the absence or presence
of ACF, M-TMCP and D-TMCP (0 or 10 µM) for 24 hours. Total RNA isolated from 1x105
cells (RNeasy mini kit; Qiagen, Valencia, CA) was reversely transcribed to cDNA by using
RT2 First Strand Kit (Qiagen, Valencia, CA). First-strand cDNA equivalent to 5 µg RNA was
applied in real-time PCR using RT2 SYBR Green Mastermix and RT² Profiler Hypoxia
Signaling Pathway PCR Arrays (Qiagen, Valencia, CA) following the manufacturer’s protocol.
qPCR conditions were 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, annealing
at 60°C for 1 min. Fluorescence was collected at 60°C step. Data was normalized to the
housekeeping gene beta-actin (ACTB). Controls were also included on each array for
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genomic DNA contamination, RNA quality, and general PCR performance. The experiments
were carried out in three independent experiments and analyzed using Applied Biosystems
7500 Fast Real-Time PCR System and RT2 Profiler PCR Array Data Analysis v3.5 (Qiagen,
Valencia, CA).

Western Blot Analysis
U87 cells were lysed with urea lysis buffer. Cell lysates (50 µg) were separated on 412% Bis-Tris sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (Invitrogen)
and transferred onto nitrocellulose membranes. The membranes were blocked for 3 h in
phosphate-buffered saline containing 5% nonfat dry milk and incubated in the same blocking
buffer at 4°C overnight with primary antibodies against HIF-1α (1:500 dilution; Novus
Biologicals, Littleton, CO) and β-actin (1:1000 dilution; Thermo Fisher Scientific, Waltham,
MA). After incubation of corresponding secondary antibodies, proteins were detected using
ECL chemiluminescence (Pierce, Rockford, IL).

Tumor Xenograft and Drug Treatment
Nude mice (NCr nu/nu) were purchased at 4 weeks of age from Taconic Farms
(Hudson, NY). Stably transduced U87/NL1α/CL1β reporter cells (5 x 106 cells in 0.2 mL of
Dulbecco’s modified Eagle’s medium) were injected subcutaneously into the right thigh of
each mouse. The animals’ tumor growth patterns and physical conditions were monitored
throughout the whole study. Tumor volume (V) was calculated using the following formula: V
= length x width x height x 0.52. Once their tumor volumes reached approximately 100 mm3,
the tumor-bearing mice were randomly categorized into four groups (8/group). They were
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then intraperitoneally (i.p.) administered 150 µL of M-TMCP (2 mg/kg in 3%DMSO in saline;
per i.p. injection), D-TMCP (2 mg/kg in 3%DMSO in saline; per i.p. injection), ACF (2 mg/kg
in 3%DMSO in saline; per i.p. injection), or saline in each groups of mice over 14 days. The
animals’ physiological parameters (weights, food intake, organ weights and motor activity),
tumor volumes, and BLI were longitudinally monitored 3 h after each injection. On day 14 of
treatment, BLI was performed before and 3 h after drug injection. All animals were handled
in accordance with The University of Texas MD Anderson Institutional Animal Care and Use
Committee guidelines. Statistical analyses were performed and fitted using with the Prism
software program (GraphPad Software, La Jolla, CA).

Organ Toxicity Assay
After 21 daily treatments of D-TMCP (doses of 0, 1, 2, 5, 10 mg/kg in 3%DMSO in
saline; 150 µl per i.p. injection), the mice were sacrificed. The animals’ physiological
parameters (weights, food intake, organ weights and motor activity) were longitudinally
monitored. Their organ samples, such as brain, heart, liver and kidney, were obtained and
fixed in 10% formalin, embedded in paraffin, and sectioned into 5-µm slices for hematoxylin
and eosin staining (H&E) or immunochemical staining of Ki67 (1:100 dilution; Thermo Fisher
Scientific, Waltham, MA).

Immunohistochemistry and Immunofluorescence
The U87/NL1α/CL1β tumor bearing mice were sacrificed after the 14th day of
treatment. Tumor samples were obtained and fixed in 10% formalin, embedded in paraffin,
and sectioned into 5-µm slices first for immunochemical staining. The primary antibodies
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used in immunochemical staining were those against CD34, GLUT-1, VEGF, Ki67 and
Annexin V. According to the host of the primary antibody, compatible secondary antibodies
(Vectastain ABC Kit; Vector Labs, Burlingame, CA) were applied. The tumor sections were
then visualized by adding diaminobenzidine (Dako, Carpinteria, CA) and counterstained with
hematoxylin in IHC or hoechst in immunofluorescent staining. Four representative regions
(10-20× objectives) in each tumor were photographed. The areas of CD34, Ki67 and
Annexin V staining were quantified under × 400 magnifications with a position pixel
algorithm using the ImageJ software program (National Institutes of Health, Bethesda, MD).

Statistical Analyses
Statistical analyses were performed using built-in statistical software programs from
Prism software program (GraphPad Software, La Jolla, CA). The specific test and significant
level of each experiment were showed in the each figure legend.
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Chapter 3: Development and Optimization of a Reporter System for
Bioluminescence Imaging of HIF-1α/HIF1β Heterodimerization
3.1 Overview of the HIF-1α/β Heterodimerization reporter system
The first aim of this study was to develop a split firefly luciferase (FLuc) fragment
complementation-based approach for quantitative bioluminescence imaging of HIF-1α/β
heterodimerization in vitro and in vivo. In this reporter system, physical interactions of two
HIF-1α/β proteins bring the N- and C-terminal fragments of FLuc close enough to
reconstitute the luciferase activity and result in photon emission (luminescence) in the
presence of the luciferase substrate. Reciprocally, the addition of inhibitor of HIF-1α/β
dimerization can disrupt the interaction and results in loss of luciferase activity. Thus, this
reporter system can be used as a drug screening tool for HIF-1 dimerization inhibitors. The
schematic illustration of the split luciferase complementation system is summarized in Figure
8.

Figure 8. Schematic of HIF-1 dimerization reporter system in drug screening.
Spontaneous association of HIF-1α12-396 and HIF-1β11-510 brings inactive fragments of firefly
luciferase into close proximity to reconstitute bioluminescence activity. Disruption of HIF1α12-396 and HIF-1β11-510 dimerization results in no bioluminescence activity.
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3.2 Optimization of HIF-1α/β heterodimerization reporter system
Using four lentiviral vector constructs with different positions of individual FLuc
fragments in relation to HIF-1α and HIF-1β (N- or C-terminal fusions through a linker; major
features showed in Fig. 9), the highest constitutive bioluminescence signal was observed
from the HEK293 cells transiently transfected with NL-1α and CL-1β or 1α-NL and 1β-CL
vector pairs (Fig. 10), whereas no Fluc activity was observed in HEK293 cells transfected
with either one of the vectors or with negative control vectors containing a nonsense
sequence in place of the PAS domains of HIF-1α and HIF-1β (NL-non or non-CL).
In consistent, similar results were also observed in U87 human glioma cells, which
were stably transduced with different pairs or individual lentiviral vectors. The magnitude of
expression of individual reporter constructs in stably transduced U87 cells was very similar,
based on co-expression levels of eGFP and mKate fluorescent proteins measured by dualcolor FACS (Fig. 11). The highest BLI signal was observed with NL-1α + CL-1β vector pair
(Fig. 12A). Overall, we found that a head-to-head or tail-to-tail combination of the fusion
proteins produced better BLI signals than head-to-tail combination did. U87 cells stably
transduced with NL-1α + CL-1β vector pairs (U87/NL1α/CL1β cells) were chosen to
establish a HIF-1α/β heterodimerization reporter system in the following experiments. The
subcellular co-localization of co-expressed eGFP and mKate reporter proteins in the
U87/NL1α/CL1β cells was also confirmed by fluorescence confocal microscopy (Fig. 12B).
In addition, the degradation half-life of the enzymatically active NL-1α + CL-1β reporter
complex in U87/NL1α/CL1β cells was about 34.12 min, as measured by BLI after
cycloheximide block (Fig. 13). In subsequent in vitro experiments, for the assessment of
inhibitors of HIF-1α and HIF-1β heterodimerization in U87/NL1α/CL1β cells, BLI was
performed no earlier than 24h post initiation of incubation.
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Figure 9. Schematic drawing shows major features of four lentiviral vectors of HIF-1α
and HIF-1β dimerization reporters. Four developed lentiviral vector constructs with
different positions of individual N- or C-terminal Fluc fragments (NL or CL) in relation to HIF1α and HIF-1β subdomains, fused through a flexible linker. Two different orientations of HIF1α12-396 linking with NL in pLVDL301 vector (pLVDL 301-NL-HIF-1α12-396 and pLVDL 301HIF-1α12-396-NL) co-expressed eGFP fluorescent protein, and another two orientations of
HIF-1β11-510 linking with CL in pLVDL312 vector (pLVDL 312- CL-HIF-1β11-510 and pLVDL
312 -HIF-1β11-510- CL) co-expressed mKate fluorescent protein.
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Figure 10. Bioluminescence in HEK293 cells transiently transfected with NL-1α and
CL-1β or 1α-NL and 1β-CL vector pairs as indicated. The highest constitutive
bioluminescence signal was observed from the HEK293 cells transiently transfected with
NL-1α and CL-1β or 1α-NL and 1β-CL vector pairs, whereas no Fluc activity was observed
in HEK293 cells transfected with either one of the vectors or with negative control vectors
containing a nonsense sequence in place of the PAS domains of HIF-1α and HIF-1β (NLnon or non-CL). Data are expressed as average photon radiance ± SEM of quadruplicate
wells. (*, P < 0.05; **, P < 0.01; ***, P < 0.005)
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Figure 11. Result of cell cytometry to evaluate eGFP and mKate coexpression level in
transduced U87 cells. A) Wt U87 cells. B, C) Single transfection of NL-1α or CL-1β in U87
cells. D,E,F,G) Dual transduction of four different complementary reporter combinations in
U87 cells.
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Figure 12. A) Highest BLI signal was observed with U87 human glioma cells transfected
with NL-1α + CL-1β vector pair, following by 1α-NL + 1β-CL (head-to-head or tail-to-tail
position), NL-1α + 1β-CL and 1α-NL + CL-1β (head-to-tail position). Result of quantitative
BLI signal measurement indicated head-to-head or tail-to-tail HIF-1 complementation pairs
demonstrated higher Fluc activity than head-to-tail pairs. B) Subcellular co-localization of coexpressed eGFP (NL-1α) and mKate (CL-1β) reporter proteins in the U87/NL1α/CL1β cells
was confirmed by fluorescence confocal microscopy. The merged panel in lower-right shows
colocalization (yellow) of NL-1α and CL-1β in cytoplasm. Fluorescence data are shown in
comparison with the corresponding bright-field image.
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Figure 13. The degradation half-life of enzymatically active NL-1α + CL-1β reporter
complex in U87/NL1α/CL1β cells. The cells were plated into a 96 well plate for 4 hours.
Cycloheximide was then mixed with culture media to block protein synthesis. The cells were
imaged for BLI by IVIS, and fluorescence using a plate reader after the addition of
cycloheximide for 0.5, 1, 2, 3, 4, 5, 6, 7, 16 and 24 hours. The half-life was calculated as
34.12 min, with a 95% confidence interval of 29.72 to 40.4 min.
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3.3 Validation of HIF-1α/β Dimerization Reporter System

3.3.1 Overexpressed HIF-1α12-396 or HIF-1β11-510 reduces the activity of HIF-1α/β
dimerization reporter
To validate the specificity of this reporter system, we transfected U87/NL1α/CL1β
reporter cells with HIF-1α12-396 or HIF-1β11-510 DNA plasmids for 24 and 48 h. The
overexpression of PAS domains of either HIF-1α or HIF-1β without FLuc fragments (which
acts as competitive inhibitors of FLuc fragment-containing interacting PAS domains),
resulted in almost 25% and 50% reduction in BLI signal intensity at 24h and 48h,
respectively (Fig. 14A); no changes in the magnitude of expression of NL-1α or CL-1β
reporter proteins were observed, based on the fluorescence levels of co-expressed eGFP
and mKate, respectively (Fig. 14B).
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Figure 14. A) In U87/NL1α/CL1β cells, the overexpression of PAS domains of either HIF-1α
(HIF-1α12-396) or HIF-1β (HIF-1β11-510), competing with PAS domain-binding sites of reporter
protein, resulted in almost 25% and 50% reduction in BLI signal intensity at 24h and 48h,
respectively. Representative data are expressed as percentage changes of photon radiance
vs. vehicle at 24 or 48h. (*, P < 0.05; **, P < 0.01; ***, P < 0.005 vs. vehicle 24h; two-way
ANOVA with Bonferroni correction) B) No changes in the magnitude of expression of NL-1α
or CL-1β reporter proteins were observed based on the fluorescence levels of co-expressed
eGFP and mKate. Data was calculated as the relative changes of fluorescence level vs.
vehicle at 24 or 48h.
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3.3.2 Hypoxia-induced upregulation of endogenous HIF-1α reduces the activity
of HIF-1α/β dimerization reporter
We induced low oxygen condition (5% O2) to create hypoxia using a modular incubator
chamber. Lack of oxygen stabilizes endogenous HIF-1α in U87/NL1α/CL1β cells and allows
endogenous HIF-1α to compete with the reporter protein binding sites. The result of western
blotting showed that incubation of U87/NL1α/CL1β cells in a hypoxic atmosphere after 24h
induced the upregulation of endogenous HIF-1α protein levels (Fig. 15A). Upregulated HIF1α acted as a competitive inhibitor of this reporter system and caused a significant decrease
(85%, p<0.005) in BLI signal at 48h of incubation (Fig. 15B) as compared to control (20%
O2), without reduction in cell viability (Fig. 15C). These results proved that this
U87/NL1α/CL1β reporter system was able to reflect the interaction between HIF-1α12-396 and
HIF-1β11-510 and can confidently be used as a platform for identifying inhibitors of HIF-1
dimerization.
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Figure 15. A) HIF-1α and β-actin protein levels were determined by Western blotting assays.
Endogenous HIF-1α increased after 24h incubation in 5% O2 , but no difference in β-actin
protein expression was noted. B) Low oxygen induced-endogenous HIF-1α stabilization also
allows HIF-1α to compete with NL-HIF-1α12-396 for dimerization with CL-HIF-1β11-510, which
causes significantly decreased BLI signals after 48 h incubation of 5% O2. (**, P < 0.01; ***,
P < 0.005 vs. 20% O2 at each time point; two-way ANOVA with Bonferroni correction) C) No
obvious reduction in cell viability between 20% O2 and 5% O2 incubation was observed at 24
or 48h.
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Chapter 4: High-Content Screening of Inhibitors of HIF-1α/HIF-1β Dimerization
in Cellulo
As part of the initial screen for novel inhibitors of HIF-1α/HIF-1β dimerization, 41
compounds were tested at 10 µM concentration. Twelve out of 41 compounds demonstrated
various degrees of inhibition of HIF-1α/HIF1β heterodimerization in U87/NL1α/CL1β reporter
cells, but without significant inhibition of cellular viability (Table. 2). The most potent
compound identified was acriflavine (ACF; compounds 7), a known inhibitor of HIF-1α/β
heterodimerization (Lee et al., 2009), which confirmed the efficacy of this screening system.
As indicated by Dr. Semanza’s group, ACF is likely to bind to HIF-1α, not HIF-1β. In
order to optimize its inhibitory effect, a systematic approach was designed to understand the
structure-activity relationships (SAR) between ACF and HIF-1α using side-chain
derivatization. The half-maximal inhibitory concentration (IC50) and cytotoxicity of each
compound were determined using the newly developed cell-based HIF-1α/β dimerization
reporter system and WST-1 cell viability assay, respectively.
As shown in Table 3, the studies were initiated by evaluating compounds (1-4), which
are structurally related to ACF. Although these compounds showed some efficacy, the
inhibition is several folds lower than ACF. We also compared the neutral and salt forms of
3,6-diaminoacridine (5) which demonstrated that salt forms ( compounds 6 and 7) were
more potent than the neutral form, which may be explained by the significantly improved
solubility of salts compared to the neutral form. The observation was also supported by
comparing compounds 3 and 4. Furthermore, the data in Table 3 shows that the elimination
of the 3,6-amino groups (compound 3 relative to 6) demonstrates the importance of the 3,6amino moiety to the efficacy of the compound. The dimethylation of the 3,6-amino groups
(compound 10 relative to 5) showed little change in efficacy, which could lead to the
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conclusion that hydrogen bonding either does not exist or does not contribute to the efficacy
of the molecule. In addition, compound 10 is not a good lead since an extended
functionalization is blocked by the unreactive nature dimethyl groups. As a result, 3,6diaminoacridine was selected for further functionalization at the amino groups to assess the
SAR in the next step. The alkyl amide variation revealed an interesting pattern, the efficacy
of the molecule was significantly enhanced by increasing the bulkiness of the alkyl group (tbutyl > isopropyl > ethyl). The same pattern was shown using a variation of ring size and
bulkiness. The three-membered ring system showed the lowest efficacy, and then the
efficacy was gradually enhanced by increasing the ring size (cyclopropyl < cyclobutyl <
cyclopentyl < cyclohexyl). Also, the bulkiness of the ring system has a profound impact on
the efficacy. The adamantyl and the tetra-methylcyclopropyl moieties showed the highest
efficacy among all molecules.
In Table 4, the amide aromatic moieties in a variety of substituents on the benzene
ring such as electron releasing groups (e.g. methyl and t-butyl) and electron withdrawing
groups (e.g. trifluoromethyl), which could negatively impacted the efficacy. Interestingly, the
heteroaromatic thiophene showed an improved efficacy compared to benzene (thiophene >
benzene > furan > isoxazole). On the other hand, the di-thiophene (compound 26) moiety
showed the highest toxicity among all molecules. It is also worth noting that increased
lipophilicity of the molecule positively impacted the efficacy. This was illustrated by the fact
that the best compounds (tetramethylcyclopropyl, adamantly, BOC, benzyl, thiophene) in
this series share a relatively higher logD value (> 5.0) with the exception of benzenesubstituted molecules, which showed lower efficacy regardless of the lipophilicity.
The SAR of the mono and the hetero-di substituted acridines were assessed for their
efficacy as shown in Table 5. N-3-(2,2,3,3-tetramethylcyclopropanecarboxamide)-6aminoacridine hydrochloric acid salt (29) was the best compound in the entire series. These
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results revealed a very interesting pattern in compounds that contain the N-3-(2,2,3,3tetramethylcyclopropanecarboxamide

moiety,

they

showed

an

improved

efficacy

(compounds 28 vs. 27 and 31 vs. 32 or 30). This conclusion demonstrates the significance
and validates the importance of the N-3-(2,2,3,3-tetramethylcyclopropanecarboxamide
moiety on the efficacy of the molecule.
In Table 5, compounds 30-32 are the biotinylated derivatives of ACF (compound 5),
and compounds 27 and 29, respectively. These compounds were synthesized to determine
the binding target (HIF-1α or HIF1-β PAS domain) in pull-down assays. The efficacy of
biotinylated

mono

N-3-acridine-(2,2,3,3-tetramethylcyclopropanecarboxamide

31

was

comparable to that of the ACF. However, the inhibitory activity of the biotinylated
compounds 30-32 was uniformly reduced by only about two-fold as compared to the
corresponding non-biotinylated compounds, which may result from interference of biotin
group in binding to HIF-1. These results confirmed that the biotinylated compounds 30-32
still bind to their targets and could be used for the pull-down assay.
Based on the results of SAR studies, the N,N'-(acridine-3,6-diyl)bis(2,2,3,3tetramethyl-cyclopropanecarboxamide)

(compound

18,

D-TMCP)

and

N-3-(2,2,3,3-

tetramethylcyclopropane-carboxamide)-6-aminoacridine hydrochloric acid salt (compound
29, M-TMCP) exhibited the most potent inhibitory activities against HIF-1α/HIF-1β
heterodimerization (IC50 = 1.0 and 0.9 µM, respectively; Fig. 16A,B) that were about 10-fold
more potent than that of the ACF (IC50 = 11.19 µM). Cellular toxicity from D-TMCP (18) and
M-TMCP (29) was observed at 80 and 50-fold higher concentrations (IC50 = 80.5 and 49.04
µM, respectively; Fig. 16C), which provides a fairly broad therapeutic window. Although the
BOC group showed comparable efficacy (IC50 = 1.6 µM), the compound was relatively toxic
(toxicity IC50 = 23.9 µM). These SAR observations may provide valuable perspectives to the
future development of HIF-1α/β disruptors.
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Table 2: The list of initially screened compounds
Chemical Names
Acrflavine (ACF)
Proflavine hemisulfate salt hydrate
3,4,9,10-perylenetetracarboxylic diimide
2-(4,5,6-TRIHYDROXY-3-OXO-3H-XANTHEN-9-YL)-BENZOIC ACID
Methylene Blue hydrate
Anthracene
BIX-01338 HYDRATE
Acridine Orange 10-nonyl bromide
1,9-PYRAZOLOANTHRONE
BIX 01294 TRIHYDROCHLORIDE HYDRATE
Dibenzothiophene
3,4,9,10-perylenetetracarboxylic 3,4,9,10-dianhydride
5-AZA-2'-DEOXYCYTIDINE
Valproic acid
5-Methylfuran-2-carbonyl chloride
trans-2-Phenyl-1-cyclopropanecarbonyl chloride
NSC-609699
N,N-DIMETHYL-10H-INDOLO(3,2-B)QUINOLIN-11-AMINE HYDROCHLORIDE
Bortezomib
3,3’-Diindolylmethane
6-Formylindolo(3,2-b)carbazole
KC7F2
AC1-004
2-Methoxyestradiol
FG-4592
IOX2
Berberine
KF58333
S409995
N-Methoxycarbonylmaleimide
RG108
Hydralazine hydrochloride
SAHA
Bis(dibenzylideneacetone)palladium(0)
Ethynyltributylstannane
Silver p-toluenesulfonate
ATTO-465
ATTO-495
ATTO-520 thio-12
methyl-acridine orange
2-amino-3-(1,2-dihydro-2-oxoquinoline-4-yl)propionic acid

57

Table 3: SAR studies of acridine like molecules
#

R

IC50 (µM)

logP

M.WT

#

R

0.52

109.1

5

17.31

Toxicity
IC50 (µM)
>50

1

31.48

Toxicity
IC50 (µM)
>50

2

54.93

139

4.0

178.1

6

20.20

21.5

3

53.0

>100

3.5

179.2

7

11.19

>50

1.93

209.2

4

27.46

>100

0.34a

321

8

20.80

15.40

4.11

265.4
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IC50 (µM)

logP

M.WT

1.93

297.2
245.7

Table 4: SAR studies of the homo-di-substituted-3,6-acridine amide.

IC50 (µM)

Toxicity
IC50 (µM)

logP

M.WT

#

IC50 (µM)

Toxicity
IC50 (µM)

logP

M.WT

9

1.57

23.90

5.48

409.5

18

1.01

80.57

6.58

457.6

10

39.48

>50

3.16

321.4

19

4.064

9.39

5.15

417.5

11

44.42

>50

3.86

349.4

20

10.44

>50

6.12

445.5

12

10.90

26.76

4.69

377.5

21

62.55

>50

7.00

553.5

13

42.66

>50

2.92

345.4

22

29.71

42.11

8.56

529.6

14

19.98

31.71

3.97

373.4

23

47.12

117.4

4.64

537.6

15

9.01

>50

5.03

401.5

24

7.719

>100

2.38

397.4

16

4.15

6.54

6.0

429.6

25

20.08

19.28

1.61

399.4

17

4.121

32.87

7.8

533.7

26

2.172

3.497

5.11

429.5

#

R

R
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Table 5: SAR assessment of the mono and hetero-substituted acridines and
biotinylated derivatives

IC50 (µM)

Toxicity
IC50 (µM)

logP

M.WT

27

5.17

53.12

5.48

409.5

28

2.894

>50

5.14

433.6

29

0.91

49.04

5.15

417.5

30

9.797

98.85

3.0

535.7

32

36.40

50.80

1.83

435.6

31

7.847

62.93

3.86

559.7

#

Structure
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Figure 16. M-TMCP and D-TMCP inhibit HIF-1α/ HIF-1β Dimerization in a dosedependent manner. A, B) BLI of U87 reporter cells treated with different dose of M-TMCP,
D-TMCP or ACF. The IC50 was determined by constructing a non-linear dose response
curve. D-TMCP or M-TMCP exhibited significantly higher inhibitory activities against HIF1α/HIF-1β heterodimerization (IC50 = 1.0 and 0.9 µM, respectively) than ACF (IC50 = 11.19
µM) (P<0.005). Representative data are expressed as percentage change of photon
radiance vs. un-treated control. Data were obtained from quadruplicate wells of three
independent experiments. C) Cell viability of different doses of M-TMCP, D-TMCP or ACF
treatments was also determined using WST-1 assay. Cellular toxicity from D-TMCP and MTMCP was observed at 80 and 50-fold higher concentrations (IC50 = 80.5 and 49.04 µM,
respectively), which provides a fairly broad therapeutic window.
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Chapter 5: Evaluation of Selected Agents as Inhibitors of HIF-1-mediated
Transcriptional Activity
5.1 M-TMCP and D-TMCP inhibit HIF-1α/ HIF-1β Dimerization, but not FLuc
fragment reconstitution
Both M-TMCP and D-TMCP were equally ineffective at 10 µM when tested in HEK293
cells transfected with an alternative well characterized rapamycin-inducible FRB-NLuc/CLucFKBP protein-protein interaction reporter system (Luker et al., 2004). The magnitude of
bioluminescent signals from HEK293/FRB-NLuc/CLuc-FKBP cells was unaffected by the
sequence of incubation with M-TMCP or D-TMCP compounds, either before or after reporter
induction with rapamycin. Thus, this study confirmed that both M-TMCP and D-TMCP do not
inhibit the trans-complementation of FLuc N- and C-terminal fragments, or enzymatic activity
of reconstituted FLuc, or generation of BLI signal (Fig. 17).
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Figure 17. No effect of ACF, M-TMCP and D-TMCP on rapamycin-induced FRBNLuc/CLuc-FKBP association in HEK-293 cells. ACF, M-TMCP and D-TMCP do not
disrupt the association of two FLuc fragment pairs. HEK-293 cells transfected with FRBNLuc/CLuc-FKBP were incubated A) with 50 nM rapamycin and treated with or without 10
µM ACF, M-TMCP and D-TMCP, or B) 10 µM vehicle or inhibitors first for 24 h and then
followed by the addition of 50 nM rapamycin. The representative bioluminescence images of
live cells in a 12-well plate are shown. Data expressed as average photon radiance ± SEM
from three independent experiments.
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5.2 M-TMCP and D-TMCP inhibit HIF-1-mediated Transcriptional Reporter
Activity
To directly assess the contribution of our inhibitors in disrupting HIF-1α/β heterodimers
and suppressing HIF-1-mediated transcriptional activity via HRE, a hypoxia-inducible
C6#4/HRE-GFP/CMV-dsRed cell reporter system with 8×HRE driven TKGFP expression
was used to examine the efficacy of selected inhibitors (Serganova et al., 2004). In
C6#4/HRE-GFP/CMV-dsRed reporter cells, both M-TMCP and D-TMCP exhibited similar
efficacy for inhibition of HIF-1-mediated transcriptional activity (IC50 = 3.88 and 2.17 µM,
respectively), which was about 2-fold better than that of the ACF (IC50 = 7.01 µM) (Fig. 18A).
Cellular toxicity from D-TMCP and M-TMCP in the C6#4/HRE-GFP/CMV-dsRed reporter
cells was observed at more than 100-fold higher concentrations and revealed no
contribution to inhibitory effect (Fig. 18B). A comparison of IC50 for both HIF-1 dimerization
and transcriptional activity of each inhibitor is presented in Figure. 19. Overall, M-TMCP and
D-TMCP showed about a log order of HIF-1 inhibitory activity as compared to ACF.
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Figure 18. Inhibitory effect of M-TMCP, D-TMCP or ACF on HIF-1 mediated
transcription. A) M-TMCP, D-TMCP or ACF inhibits HRE-driven transcription under
hypoxia in C6#4/HRE-GFP/CMV-dsRed reporter cells. The reporter cells were incubated
with different concentrations of M-TMCP, D-TMCP or ACF for 24 h. Constitutively expressed
DsRed florescent protein in C6#4/HRE-GFP/CMV-dsRed cells were used as reference. The
relative changes of GFP/DsRed expression vs. control was calculated as an indication of
HRE-driven transcription levels in cells treated with inhibitors at each concentration. The
result showed that IC50 of HIF-1 transcriptional activity in the cells treated with M-TMCP, DTMCP or ACF is 3.88 µM, 2.17 µM and 7.01 µM, respectively. Data were obtained from
quadruplicate wells of three independent experiments. B) IC50 of cellular toxicity of
C6#4/HRE-GFP/CMV-dsRed cells treated with M-TMCP, D-TMCP or ACF is almost 10
times higher than the IC50 of HIF-1 transcriptional activity. (*, P < 0.05; **, P < 0.01; ***, P <
0.005; two-way ANOVA with Bonferroni correction)

65

Figure 19. Comparison of IC50 of M-TMCP, D-TMCP and ACF in U87/NL1α/CL1β
reporter cells or C6#4/HRE-GFP/CMV-dsRed HIF-1 transcriptional activity reporter
cells. (*, P < 0.05; **, P < 0.01; ***, P < 0.005; two-way ANOVA with Bonferroni correction)

66

5.3 M-TMCP and D-TMCP inhibit mRNA expression of HIF-1-dependent genes
in hypoxia
To further investigate whether the selected inhibitors were effective in transcriptionally
regulating hypoxia-induced genes in tumorigenesis, the human hypoxia signaling pathway
array was used to profile the expression of 84 hypoxia-associated genes (Tab. 6), including
genes related to stress response, angiogenesis, metabolism, DNA damage and repair, HIF
signaling transcription factors and HIF interacting proteins. First, non-supervised hierarchical
clustering analysis of our entire qRT-PCR data was displayed as a heat map with
dendrograms to indicate co-regulated genes across groups (Fig. 20). Comparison of gene
expression patterns in wild-type U87 cells cultured under conditions of normoxic, hypoxic
conditions or hypoxic U87 cells treated with M-TMCP or D-TMCP demonstrated significant
differences in the magnitudes of expression of multiple HIF1-dependent genes. The
hierarchical cluster analysis also revealed that the gene expression pattern in treatment
group were more similar to that of the normoxic group, rather than hypoxic groups. This
finding confirmed the assertion that M-TMCP and D-TMCP intervene with the expression of
hypoxia-responsive genes.
Furthermore, hierarchical cluster analysis revealed that several clusters of genes
upregulated by hypoxia have been significantly inhibited by 24h treatment with ACF, MTMCP or D-TMCP (cluster 3.2.1.2 in Figure. 20). Disruption of hypoxia-induced HIF-1
transcriptional activity by ACF, M-TMCP or D-TMCP treatment resulted in a more profound
inhibition in one sub-cluster of genes (i.e., 3.2.1.2.1) as compared to other sub-clusters (i.e.,
3.2.1.2.2), suggesting the genes in 3.2.1.2.2 may not be directly or solely regulated through
HIF-1 complex but other pathways. The subset of data including representative genes from
these two clusters is presented in Figure 21. Notably, several genes which are upregulated
in hypoxia and promote tumorigenesis (Hirota and Semenza, 2006, Semenza, 2001, Zhang
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et al., 2012, Tacchini et al., 2001, Zou et al., 2013, Iyer et al., 1998, Garayoa et al., 2000,
Cormier-Regard et al., 1998, Riddle et al., 2000, Ryan et al., 1998, Manalo et al., 2005,
Bhattacharyya and Tobacman, 2012, Semenza et al., 1994) were significantly downregulated by ACF, M-TMCP or D-TMCP treatment, including: vascular endothelial growth
factor A (VEGFA); facilitated glucose transporter member 1 (GLUT-1); hexokinase 2 (HK2),
enolase 1 (ENO1), notch 1 (NOTCH1), plasminogen activator (PLAU), collagen type I alpha
(COL1A1), procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3); whereas lesser
extend of downregulation was observed for: glucose-6-phosphate isomerase (GPI);
angiopoietin-like 4 (ANGPTL4), including adrenomedullin (ADM), and insulin-like growth
factor binding protein 1 (IGFBP1). These results confirmed that M-TMCP and D-TMCP can
suppress the expression of pro-tumorigenic genes and disrupt hypoxia adaptive cascade in
tumor by inhibiting HIF-1α/β complex.
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Table 6: 84 hypoxia-associated genes in human hypoxia signaling pathway array
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Position

Unigene

Refseq

Symbol

Description

A01
A02
A03
A04
A05
A06
A07
A08
A09
A10
A11

Hs.441047
Hs.320151
Hs.494321
Hs.9613
Hs.433291
Hs.459070
Hs.624291
Hs.728782
Hs.728893
Hs.23118
Hs.2490

NM_001124
NM_006412
NM_015239
NM_001039667
NM_003491
NM_014862
NM_004324
NM_003670
NM_001168
NM_001738
NM_033292

ADM
AGPAT2
AGTPBP1
ANGPTL4
NAA10
ARNT2
BAX
BHLHE40
BIRC5
CA1
CASP1

A12
B01
B02
B03
B04
B05
B06
B07
B08
B09

Hs.502302
Hs.690198
Hs.150793
Hs.172928
Hs.459759
Hs.695
Hs.95120
Hs.631844
Hs.289123
Hs.348418

NM_001752
NM_001791
NM_001275
NM_000088
NM_004380
NM_000100
NM_134268
NM_001348
NM_006400
NM_001938

CAT
CDC42
CHGA
COL1A1
CREBBP
CSTB
CYGB
DAPK3
DCTN2
DR1

B10
B11
B12
C01
C02
C03
C04

Hs.195080
Hs.520703
Hs.517145
Hs.517517
Hs.468410
Hs.2303
Hs.643580

NM_001397
NM_001402
NM_001428
NM_001429
NM_001430
NM_000799
NM_017892

ECE1
EEF1A1
ENO1
EP300
EPAS1
EPO
PRPF40A

C05

Hs.654784

NM_002067

GNA11

C06
C07
C08
C09
C10
C11
C12
D01
D02
D03
D04
D05
D06
D07
D08

Hs.466471
Hs.76686
Hs.523443
Hs.597216
Hs.500788
Hs.420830
Hs.406266
Hs.517581
Hs.528299
Hs.277704
Hs.523414
Hs.642938
Hs.1722
Hs.654458
Hs.532082

NM_000175
NM_000581
NM_000518
NM_001530
NM_017902
NM_152794
NM_000189
NM_002133
NM_006388
NM_006389
NM_000612
NM_000596
NM_000575
NM_000600
NM_002184

GPI
GPX1
HBB
HIF1A
HIF1AN
HIF3A
HK2
HMOX1
KAT5
HYOU1
IGF2
IGFBP1
IL1A
IL6
IL6ST

D09

Hs.430551

NM_003870

IQGAP1

Adrenomedullin
1-acylglycerol-3-phosphate O-acyltransferase 2
ATP/GTP binding protein 1
Angiopoietin-like 4
N(alpha)-acetyltransferase 10, NatA catalytic subunit
Aryl-hydrocarbon receptor nuclear translocator 2
BCL2-associated X protein
Basic helix-loop-helix family, member e40
Baculoviral IAP repeat containing 5
Carbonic anhydrase I
Caspase 1, apoptosis-related cysteine peptidase (interleukin
1, beta, convertase)
Catalase
Cell division cycle 42 (GTP binding protein, 25kDa)
Chromogranin A (parathyroid secretory protein 1)
Collagen, type I, alpha 1
CREB binding protein
Cystatin B (stefin B)
Cytoglobin
Death-associated protein kinase 3
Dynactin 2 (p50)
Down-regulator of transcription 1, TBP-binding (negative
cofactor 2)
Endothelin converting enzyme 1
Eukaryotic translation elongation factor 1 alpha 1
Enolase 1, (alpha)
E1A binding protein p300
Endothelial PAS domain protein 1
Erythropoietin
PRP40 pre-mRNA processing factor 40 homolog A (S.
cerevisiae)
Guanine nucleotide binding protein (G protein), alpha 11 (Gq
class)
Glucose-6-phosphate isomerase
Glutathione peroxidase 1
Hemoglobin, beta
Hypoxia inducible factor 1, alpha subunit
Hypoxia inducible factor 1, alpha subunit inhibitor
Hypoxia inducible factor 3, alpha subunit
Hexokinase 2
Heme oxygenase (decycling) 1
K(lysine) acetyltransferase 5
Hypoxia up-regulated 1
Insulin-like growth factor 2 (somatomedin A)
Insulin-like growth factor binding protein 1
Interleukin 1, alpha
Interleukin 6 (interferon, beta 2)
Interleukin 6 signal transducer (gp130, oncostatin M
receptor)
IQ motif containing GTPase activating protein 1
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Position

Unigene

Refseq

Symbol

D10
D11

Hs.708128
Hs.479754

NM_003685
NM_000222

KHSRP
KIT

D12
E01
E02
E03
E04
E05
E06
E07
E08
E09
E10
E11
E12
F01
F02
F03
F04
F05
F06
F07
F08
F09
F10
F11
F12
G01
G02
G03
G04
G05
G06
G07
G08
G09
G10
G11
G12
H01
H02
H03
H04
H05
H06
H07
H08
H09

Hs.551506
Hs.194236
Hs.356769
Hs.159410
Hs.73133
Hs.179718
Hs.709191
Hs.495473
Hs.1832
Hs.493767
Hs.66581
Hs.517216
Hs.146100
Hs.77274
Hs.153357
Hs.103110
Hs.491440
Hs.43322
Hs.82793
Hs.591286
Hs.654583
Hs.652114
Hs.265174
Hs.498569
Hs.546287
Hs.515500
Hs.473721
Hs.380691
Hs.467097
Hs.503178
Hs.25723
Hs.380973
Hs.435609
Hs.474783
Hs.75318
Hs.80658
Hs.73793
Hs.534255
Hs.412707
Hs.728776
Hs.592355
Hs.520640
N/A
N/A
N/A
N/A

NM_002299
NM_000230
NM_000528
NM_014484
NM_005954
NM_002466
NM_000625
NM_017617
NM_000905
NM_001161
NM_006849
NM_003768
NM_015553
NM_002658
NM_001084
NM_005036
NM_001009552
NM_006251
NM_002795
NM_002852
NM_000964
NM_000991
NM_000994
NM_002952
NM_001011
NM_005500
NM_006516
NM_001042
NM_003089
NM_003128
NM_006396
NM_006937
NM_000360
NM_003312
NM_006000
NM_003355
NM_003376
NM_004048
NM_000194
NM_012423
NM_002046
NM_001101
SA_00105
SA_00104
SA_00104
SA_00104

LCT
LEP
MAN2B1
MOCS3
MT3
MYBL2
NOS2
NOTCH1
NPY
NUDT2
PDIA2
PEA15
IPCEF1
PLAU
PLOD3
PPARA
PPP2CB
PRKAA1
PSMB3
PTX3
RARA
RPL28
RPL32
RPS2
RPS7
SAE1
GLUT-1
GLUT-4
SNRNP70
SPTBN1
SSSCA1
SUMO2
TH
TST
TUBA4A
UCP2
VEGFA
B2M
HPRT1
RPL13A
GAPDH
ACTB
HGDC
RTC
RTC
RTC

Description
KH-type splicing regulatory protein
V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
homolog
Lactase
Leptin
Mannosidase, alpha, class 2B, member 1
Molybdenum cofactor synthesis 3
Metallothionein 3
V-myb myeloblastosis viral oncogene homolog (avian)-like 2
Nitric oxide synthase 2, inducible
Notch 1
Neuropeptide Y
Nudix (nucleoside diphosphate linked moiety X)-type motif 2
Protein disulfide isomerase family A, member 2
Phosphoprotein enriched in astrocytes 15
Interaction protein for cytohesin exchange factors 1
Plasminogen activator, urokinase
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3
Peroxisome proliferator-activated receptor alpha
Protein phosphatase 2, catalytic subunit, beta isozyme
Protein kinase, AMP-activated, alpha 1 catalytic subunit
Proteasome (prosome, macropain) subunit, beta type, 3
Pentraxin 3, long
Retinoic acid receptor, alpha
Ribosomal protein L28
Ribosomal protein L32
Ribosomal protein S2
Ribosomal protein S7
SUMO1 activating enzyme subunit 1
Facilitated glucose transporter, member 1
Facilitated glucose transporter, member 4
Small nuclear ribonucleoprotein 70kDa (U1)
Spectrin, beta, non-erythrocytic 1
Sjogren syndrome/scleroderma autoantigen 1
SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)
Tyrosine hydroxylase
Thiosulfate sulfurtransferase (rhodanese)
Tubulin, alpha 4a
Uncoupling protein 2 (mitochondrial, proton carrier)
Vascular endothelial growth factor A
Beta-2-microglobulin
Hypoxanthine phosphoribosyltransferase 1
Ribosomal protein L13a
Glyceraldehyde-3-phosphate dehydrogenase
Actin, beta
Human Genomic DNA Contamination
Reverse Transcription Control
Reverse Transcription Control
Reverse Transcription Control
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H10
H11
H12

N/A
N/A
N/A

SA_00103
SA_00103
SA_00103

PPC
PPC
PPC

Positive PCR Control
Positive PCR Control
Positive PCR Control

72

Figure 20. mRNA expression profile of human HIF-1 related genes in normoxic U87
cells and hypoxic U87 cells treated with HIF-1 dimerization inhibitors. Two-dimensional
hierarchical clustering of the data matrix consisting of 84 genes by five different treatment
groups, normoxia, hypoxia, hypoxia and treated with ACF, M-TMCP and D-TMCP,
repectively. Genes (rows) and groups (columns) were clustered independently by
hierarchical clustering. Three main clusters are numbered. The gene expression in the
subcluster of 3.2.1.2.1 was down-regulated in all three inhibitor groups compared to hypoxia
and relatively closer to the expression in normoxia. In cluster of 3.2.1.2.2, the gene
expression was also decreased in the inhibitor treated groups, but not as dramatically as the
genes in cluster of 3.2.1.2.1. This indicates that the genes in 3.2.1.2.2 may not be strictly
controlled by HIF-1 but also other signaling pathways. Data shown are averages of triplicate
qRT-PCR measurements.
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Figure 21. The mRNA expression of selective tumor progression and angiogenesisrelated genes was significantly decreased in hypoxic U87 glioma cells treated with MTMCP and D-TMCP. U87 cells were incubated under normoxia or hypoxia in absence or
presence of the inhibitors at concentration of 10 µM for 24 hours. Total RNA was isolated
from the whole-cell lysates for profiling of hypoxia-related genes by qRT-PCR. Fold changes
of mRNA levels relative to normoxia were calculated as 2 (-Avg.(Delta(Ct)). Mean ± SEM (n=3).
Note the scales of fold changes in two plots are different.
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Chapter 6: Evaluation of Therapeutic Efficacy of Selected Inhibitors in Tumor
Xenograft Bearing Mice
6.1 Imaging Inhibition of HIF-1α /HIF1-β Heterodimerization and Antitumor
Therapeutic Efficacy by M-TMCP and D-TMCP in Tumors in Vivo
The anti-tumor efficacy of selected HIF-1 inhibitors was evaluated in nude mice
bearing subcutaneous (s.c.) tumor xenografts developed from the U87/NL1α/CL1β reporter
cells. Vehicle, M-TMCP, D-TMCP or ACF was administered by daily intraperitoneal (i.p.)
injection to tumor xenograft mouse. Treatment was initiated 14 days after implantation, at
which time the tumors had grown to an average of approximately 100 mm3 in all groups, and
continued for another 14 days (Fig. 22). Daily administration of either M-TMCP or D-TMCP
(2 mg/kg in 3%DMSO in saline; 150 µl i.p.) in mice, resulted in a significant inhibition of
bioluminescence signals from the reporter tumors as early as 3 days post treatment (Fig. 23)
and significant inhibition of tumor growth, which was manifested by prolongation of tumor
doubling times - 4.86 and 5.19 days, respectively, when compared to vehicle-treated control
mice (doubling time of 3.88 days) (Fig. 24). Daily treatment of mice with ACF (2 mg/kg in 3%
DMSO in saline; 150 µl i.p.) resulted in a less dramatic inhibition of the reporter activity (Fig.
23A) and tumor growth (Fig. 24) (doubling time of 4.42 days), as compared to M-TMCP or
D-TMCP-treated mice. In addition, treatments of M-TMCP or D-TMCP at the dosage of 2
mg/kg demonstrated more significant log10 tumor cell kill (0.453 and 0.45, respectively), as
compared to ACF (0.387) (Bissery et al., 1991) in Figure 25. Statistically significant
differences in average tumor sizes between groups of mice treated with either M-TMCP or
D-TMCP versus the ACF-treated group were observed staring from the 9th day of treatment
(P < 0.05 and P < 0.001, respectively). Noteworthy, there were no differences between the
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treated and control groups in the dynamics of body weight during treatment (Fig. 26),
indicating a low systemic toxicity of the treatment doses used.
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Figure 22. Schematic tumor growth and treatment flow. Nude mice were implanted with
5 x 106 U87/NL1α/CL1β reporter cells at Day 0. At Day 14, tumor volumes reached
approximately 100 mm3. The
hese tumor-bearing mice were then randomly categorized into
four groups (6 mice / group). 150 µL of M-TMCP (2 mg/kg in 3%DMSO in saline),
saline D-TMCP
(2 mg/kg in 3%DMSO in saline
saline), ACF (2 mg/kg in 3%DMSO in saline),
), or saline was i.p
injected into each groups of mice over the next 14 days. The tumor growth patterns and
physical conditions were monitored throughout the study
study.
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Figure 23. HIF-1α/β dimerization inhibition of M-TMCP and D-TMCP on U87/NL1α/CL1β
glioma cancer xenograft model. A) Monitoring HIF-1 disruption in mice by BLI. The BL
signal decrease significantly in M-TMCP and D-TMCP group only after 4 day of repeated
treatment. Data are presented as log (total photon radiance) ± SEM of six mice in each
group imaged repeatedly over the course of the experiment. B) Bioluminescent imaging of
four representative Nu/Nu mice with different treatments. The BLI images were taken 4 h
after daily treatment.
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Figure 24. Anti-tumor effect of M-TMCP and D-TMCP on U87/NL1α/CL1β human
glioma xenograft in mice. The tumor growth patterns of mice during the course of
treatment. Significant prolongation of tumor doubling times in M-TMCP and D-TMCP treated
groups (4.86 and 5.19 days, respectively), as compared to vehicle-treated control mice
(doubling time of 3.88 days). Daily treatment of mice with ACF resulted in a less dramatic
inhibition of tumor growth (doubling time of 4.42 days). Volume mean ± SEM (n = 8) is
shown.
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Figure 25. Log tumor cell kill of M-TMCP and D-TMCP on U87/NL1α/CL1β
U87/NL1α
human
glioma xenograft in mice.. M-TMCP and D-TMCP treated groups demonstrated higher log
tumor cell kill values (0.453 and 0.45, respectively), as compared to ACF-treated
ACF
mice
(0.387). Log10 (tumor volume in mm3) ± SEM (n = 8) is shown.
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Figure 26. No loss in body weights of U87/NL1α/CL1β xenograft-bearing mice treated
with HIF-1 dimerization inhibitors. Weights of the tumor xenograft bearing mice treated
with vehicle (black), ACF (red), M-TMCP (Blue) or D-TMCP (Green) were measured
throughout the experiment. Mean ± SEM (n = 6) is shown.
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6.2 Effects of M-TMCP and D-TMCP Treatment on Tumor Vascularization,
Proliferation, and Apoptosis in vivo
To determine the ability of M-TMCP and D-TMCP on tumor prognosis, mice bearing
U87/NL1α/CL1β xenograft were treated with vehicle, ACF, M-TMCP and D-TMCP for 14
days.

After

the

last

dose,

tumor

samples

were

collected

and

evaluated

by

immunohistochemical analysis. At the end of the 14th day treatment, immunohistochemical
analysis of U87/NL1α/CL1β tumor tissue samples demonstrated significant differences in
microvacular morphology, tumor cell proliferative activity and apoptosis in treated groups
versus control group. Tumors in the vehicle-treated control group had characteristically high
levels of VEGF and GLUT-1 expression, abnormally increased microvascular morphology
and density (CD34+), high proliferative activity (high Ki67 labeling index) and low
percentage of Annexin V+ apoptotic cells (Fig. 27). Notably, in control tumors the
expression of VEGF and GLUT-1 were observed in avascular and apparently hypo- or nonperfused microvessels, whereas no expression of VEGF and GLUT-1 were observed within
120-150 µm around well perfused microvessels (Fig. 28, 29). In contrast, the expression of
VEGF and GLUT-1 were markedly decreased in ACF, M-TMCP, D-TMCP -treated tumors
(Fig. 27A), along with a statistically significant reduction in the number, size, and branching
of CD34+ microvessels (Fig. 27B), decreased in tumor cell proliferation (Fig. 27C), and
increased percentage of apoptotic cells (Fig. 27D; Fig. 30). These IHC results suggested
that our identified HIF-1 dimerization inhibitors hit their therapeutic target by suppressing
HIF-1 dependent signaling pathway associated with reduced tumor vascularization, cellular
invasiveness and modified metabolic micro-environment.
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Figure 27. M-TMCP and D-TMCP reduced tumor vascularization, modified metabolic
micro-environment, inhibited cellular invasiveness, and induced cellular apoptosis.
Mice with approximately 100mm3 U87/NL1α/CL1β cells xenografts were treated for 14 days
and euthanized on day 28. A) Tumor samples were collected after the last treatment and
analyzed by immunohistochemistry for VEGF, GLUT-1, CD34, Ki67 and Annexin V. Scale
bar: 200 µm. B) Total pixel area of VEGF in different treatment. Significantly suppression of
VEGF expression were observed in ACF, M-TMCP and D-TMCP treated tumor samples C)
Inhibitor treatment decreased cellular proliferation determined by Ki67, resulting in the tumor
growth retardation in xenograft models. D) All tumor samples treated with the inhibitors
demonstrated significantly higher apoptotic index comparing to control samples. The stained
area of CD34 and Ki67 in 20 fields was quantified under × 400 magnifications (n = 3, each
treatment). The stained area of Annexin V in 5 fields was quantified under × 800
magnifications (n = 3, each treatment). *, P < 0.05; ***, P < 0.005 vs. control (two-way
ANOVA with Bonferroni correction)
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Figure 28. Immunofluorescent staining for evaluating expression of VEGF (Green)
with associated tumor vascular structure (CD34+; Red) in U87/NL1α/CL1β tumors.
Mice bearing U87/NL1α/CL1β xenograft were treated with vehicle, ACF, M-TMCP and DTMCP (2 mg/kg in 3%DMSO in saline; 150 µl i.p.) for 14 days. After the last dose, tumor
samples were collected and evaluated by immunohistochemical analysis. In control tumors,
the expression of VEGF was observed in avascular and apparently hypo- or non-perfused
microvessels, whereas much lesser expression of VEGF was observed within 120-150 µm
around well perfused microvessels. In addition, the expression of VEGF was markedly
decreased in ACF, M-TMCP, D-TMCP -treated tumors along with a statistically significant
reduction in the number, size, and branching of CD34+ microvessels. Scale bar: 100 µm.
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Figure 29. Immunofluorescent staining for evaluating expression of GLUT-1 (Green)
with associated tumor vascular structure (CD34+; Red) in U87/NL1α/CL1β tumors.
Mice bearing U87/NL1α/CL1β xenografts were treated with vehicle, ACF, M-TMCP and DTMCP (2 mg/kg in 3%DMSO in saline; 150 µl i.p.) for 14 days. After the last dose, tumor
samples were collected and evaluated by immunohistochemical analysis. The expression of
GLUT-1 was markedly decreased in ACF, M-TMCP, D-TMCP -treated tumors. In addition,
the expression of GLUT-1 was often observed in avascular area. Scale bar: 100 µm.
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Figure 30. Immunofluorescent staining for evaluating expression of Annexin V (Green)
with associated tumor vascular structure (CD31+; Red) in U87/NL1α/CL1β tumor. Mice
bearing U87/NL1α/CL1β xenograft were treated with vehicle, ACF, M-TMCP and D-TMCP
(2 mg/kg in 3%DMSO in saline; 150 µl i.p.) for 14 days. After the last dose, tumor samples
were collected and evaluated by immunohistochemical analysis. The percentage of
apoptotic cells (Annexin V positive) was slightly increased in ACF, M-TMCP, D-TMCP treated tumors verse control, along with a statistically significant reduction in the number,
size, and branching of CD34+ microvessels. Scale bar: 100 µm.
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6.3 Assessment of systemic toxicity after chronic administration of D-TMCP in
vivo
To examine whether the administration of D-TMCP caused drug-induced organ toxicity
in nude mice, a separate group of normal mice were treated for three weeks with daily
administration of 0, 1, 2, 5, or 10 mg/kg of D-TMCP (in 3%DMSO in saline; 150 µl i.p.). All
different dosage treatments of D-TMCP did not cause any notable histological changes in
brain, heart, lung, liver, spleen, pancreas, kidney, and testis (Fig. 31 and 32), suggesting
that D-TMCP was well tolerated in mice at doses up to 10 mg/kg.
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Figure 31. No physiological changes observed after repeated D-TMCP treatment,
ranging from 1 to 10 mg/kg, for up to 21 days. Histology analysis of organs from nude
mice after 21 days of repeated D-TMCP treatement. After mice were sacrificed, their major
organs were collected and fixed in formalin and paraffin-embedded. No abnormalities in the
tissue physiology were observed under the microscope in the H&E sections (400×
magnification). Scale bar: 200 µm.
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Figure 32. No abnormal cellular proliferation observed after repeated D-TMCP
treatment, ranging from 1 to 10 mg/kg, for up to 21 days. Histology analysis of organs
from nude mice after 21 days of repeated D-TMCP treatment. Mice major organs were
collected, fixed in formalin, paraffin-embedded and stained with Ki67 IHC. The expression of
Ki67 between each group was similar. No abnormal cellular proliferation was observed.
Scale bar: 200 µm.
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Chapter 7: Summary and Discussion
HIF-1 participates in energy metabolism, angiogenesis, and proliferation in tumors.
Enhanced HIF-1 expression is a common feature of most solid tumors and often leads to
poor clinical outcomes. Targeting HIF-1 has long been recognized as an effective yet
challenging therapeutic strategy for cancer. Despite efforts have been made to identify small
molecule inhibitors that target HIF-1 pathway, the strategies reported so far were mostly
used in vitro yeast two-hybrid-like or cell-based reporter assays (Mahon et al., 2001, Bex et
al., 2007, Li et al., 2008, Cockman et al., 2006, Schwartz et al., 2009, Tan et al., 2005,
Narita et al., 2009, Semenza, 2007a, Mooring et al., 2011, Lee et al., 2009). The major
drawback of in vitro yeast two-hybrid-like assays is the possibility of identifying biologically
irrelevant interactions that may never occur in vivo, while the cell-based HIF-1-targeted
assays offer the advantage of recapitulating relevant signaling in vivo. Most of the currently
used cell-based HIF-1 assays utilize DNA constructs containing reporter genes under the
control of multiple copies of HREs, usually the promoter region of VEGF. The binding of HIF1 to HREs transactivates its downstream reporter gene, such as fluorescent or luciferase
protein. This type of reporter design provides only the final result of HIF-1 transcriptional
activity, with no information about the mechanisms of action. Therefore, in the present study,
an exclusive HIF-1-targeted screening system was designed focusing on specific proteinprotein interaction domains (PAS-AB) in HIF-1α and HIF-1β to identify only selective
inhibitors of HIF-1α/β dimerization. The orientation of reporter vector was also determined to
optimize the complementation assay for enhanced induction of HIF-1α/β dimerization.
Moreover, the HIF-1α/β dimerization cell-based reporter system was established via
lentiviral transduction instead of commonly used transient transfection, in which the level of
gene expression decreases quickly over time. This stably transduced U87/NL1α/CL1β cells
can provide robust and quantifiable results in live cells or animal in near real time.
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Although HIF-1α/HIF-1β and HIF-2α/HIF-1β share some similar properties, recent
studies have suggested that they demonstrate distinct characteristics for both isoforms
(Loboda et al., 2012, Loboda et al., 2010, Ratcliffe, 2007, Hu et al., 2003). For example, in
regulation of angiogenesis, HIF-1α/HIF-1β and HIF-2α/HIF-1β may exert counteractive
influences on angiogenic mediators. In hypoxia, HIF-1α/HIF-1β and HIF-2α/HIF-1β regulate
VEGF expression in the same manner (Jones et al., 2001). However, while HIF-1α
decreases interleukin-8 (IL-8) expression, the overexpression of HIF-2α results in increase
of IL-8 (Florczyk et al., 2011, Loboda et al., 2009). The relationships between HIF-1α and
HIF-2α in regulating different signal pathways remain to be explored further. These
paradoxical effects of HIF-1α and HIF-2α in cancer may influence therapeutic approaches in
developing HIF-1 targeted drugs. The discovery of HIF-1α was earlier than HIF-2α, and
intensive investigation have led to better understanding of HIF-1α/HIF-1β in cellular
signaling network and pathological situations. Therefore, the design of current reporter
system specifically aimed to identify the inhibitors of HIF-1α/HIF-1β heterodimers. However,
HIF-1α and HIF-2α share a high degree of homology. There is still a possibility that inhibitors
identified using this HIF-1α/HIF-1β reporter system may also disrupt the formation and
function of HIF-2α/HIF-1β heterodimer.
There is an increasing interest in identification of small molecular inhibitors that
target protein-protein interactions that are essential for stabilization and formation of the
HIF-1α/HIF-1β heterodimer. Although several studies have demonstrated that some
compound pose significant inhibitory activities in cell free assays, many failed during cellbased assays because of their poor pharmacokinetic properties, such as cell membrane
permeability or absorption (Park et al., 2006a, Koh et al., 2008, Mooring et al., 2011,
Yewalkar et al., 2010). Herein, this newly developed high-throughput system was designed
to screen potential HIF-1α/β inhibitors in live cells so that cell permeability or absorption of
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inhibitors would be reflected in the IC50 value. Using a cell based assay, Lee et al (2009)
previously have identified acriflavine (ACF), a mixture 3,6-diamino-10-methylacridinium
chloride and 3,6-diaminoacridine, as an inhibitor of HIF-1α/β dimerization and transcriptional
activity (Lee et al., 2009). The high potency of ACF was confirmed using the newly
developed reporter system in the initial screen of HIF-1 inhibitory compound library.
However, this study was based on a mixture of two compounds. As a result, it was not clear
which of these two compounds is responsible for the potency. To this end, the utilization of
structure–activity relationships led to the discovery of a mono- and di-substituted 3,6diaminoacridine

analogues

that

have

significant

inhibition

of

the

HIF-1α/HIF-1β

heterodimeric interaction. The functionalization at the 3,6-position of the diaminoacridine to
assess potency was critical for understanding the structure-activity relationships in this
series and for identifying compounds with improved pharmacodynamic profiles.
The PAS domain in HIF-1α or HIF-1β can be sub-categorized into PAS-A and PAS-B
subdomains, both of which contribute to the heterodimerization. Card et al. demonstrated
that a point mutation in the PAS-B subdomain of HIF-2α can disrupt HIF-2α/HIF-1β
heterodimer formation in vitro, and further attenuate hypoxia transcriptional responses in
living cells. This result suggested the possibility of disrupting HIF-1 heterodimerization by
partially blocking a single PAS subdomain. In Lee et al. study, it was showed that ACF binds
to the PAS-B subdomain of HIF-1α, thereby disrupting HIF-1α/β dimerization and leading to
inhibition of HIF-1 transcriptional activity. Therefore, it is most likely that M-TMCP and DTMCP also bind to the PAS domain of HIF-1α, based on their similarity in chemical structure
with ACF. In such case, M-TMCP or D-TMCP binds with stabilized HIF-1α only in hypoxic
regions, which also introduces an opportunity to use M-TMCP or D-TMCP as HIF-1α
targeted hypoxia imaging agent.
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Treatment with M-TMCP or D-TMCP for two weeks resulted in a significant inhibition
of tumor growth. The balance between cell proliferation and cell death determines the
growth dynamics of tumor tissue. The decrease in tumor cell proliferation (Ki67+ labeling
index) and the increase in the number of apoptotic cells, as compared to control, explain the
tumor shrinkage observed in all three treatment groups. In addition, M-TMCP or D-TMCP
demonstrated significant antitumor activity that was associated with the decrease of VEGF
and GLUT-1 expression in in vivo U87 human glioma mice models. These changes were
paralleled by the downregulation of pro-tumorigenic genes involved in HIF-1 signaling
network observed in the qRT-PCR arrays. Early decreases in BLI signals from the xenograft
tumors treated with M-TMCP and D-TMCP indicated that our reporter system promptly
detect HIF-1α/β disruption in tumors, which preceded the retardation of tumor growth.
Some concerns may be raised about whether the identified HIF-1 inhibitors are too
cytotoxic to serve as drug leads. In this study, D-TMCP inhibited HIF-1 activity at
concentrations that did not affect proliferation or survival of the cells. Daily administration of
1-10 mg/kg D-TMCP in nude mice for 21 days did not result in distinct changes in the
morphology or function of major vital organs. Although acridine analogs are known for
antimicrobial activity (Wainwright, 2001, Wainwright, 2000) and even some anti-tumor
activity (Patel et al., 2010), for many years their potential roles as anti-cancer drugs have not
been fully explored. Herein, this study clarified their mechanism of action at the transcription
level and provided evidence for antitumor efficacy of acridine derivatives in in vivo small
animal tumor models. However, to move the inhibitors into clinical trials, additional
preclinical studies are still required.
In conclusion, a novel methodology was developed for exploring selective HIF-1α/β
dimerization inhibitors in cellulo and in vivo. Using this HIF-1α/β heterodimerization
screening system, the structure-activity relationship of acridine analogues was established,
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which provides valuable information for future optimizing HIF-1α/β inhibitor from chemical
libraries. Moreover, the most promising drug candidates, M-TMCP and D-TMCP, exhibit
significant antitumor efficacy with no physiological toxicity and show great clinical potential
as a dual therapeutic and diagnostic agent. The identification of selective HIF-1α/β inhibitors
is not only beneficial for therapeutic implications, but also as an analytic tool to further
explore the role of HIF-1α/β in human cancers.
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Chapter 8: Future Direction
In the future, the therapeutic potential of M-TMCP or D-TMCP will be further
evaluated using different animal models. In addition, we will investigate whether the
combination of M-TMCP or D-TMCP with other treatments (e.g. chemotherapy, radiotherapy,
or immunotherapy) may be more effective in achieving tumor remission and increasing
survival rate. On the other aspect, M-TMCP or D-TMCP will be labeled with different
radionuclides, such as

18

F or

188

Re, to explore the possibility of developing new HIF-1α

imaging agent. After isotopic labeling, their efficacy will need to be re-evaluated. If
successful, this HIF-1α imaging agent can serve as a hypoxia indicator to evaluate the
treatment response of anti-cancer drugs or radiation therapy. In the meantime, more
compound libraries will be explored using this high content HIF-1α/β dimerization screening
system to identify potential drug leads.
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